The Weekly Term Sheet (2026-W09)
The week of February 22–26, 2026 recorded approximately $16.0 billion in announced and completed biotech and healthcare transaction value, headlined by Gilead Sciences' $7.8 billion definitive agreement to acquire Arcellx, GSK's $950 million acquisition of 35Pharma, and Asahi Kasei's €780 million (~$920 million) acquisition of Aicuris — the largest Japanese pharma deal in Europe this year. Novartis AG's $159 million divestiture of its India-listed subsidiary to a private equity consortium completed the M&A roster.
On the licensing side, Astellas and Vir Biotechnology's $1.7 billion collaboration for VIR-5500, Novo Nordisk's $2.1 billion oral biologics collaboration with Vivtex, Harbour BioMed's $1.2 billion Solstice Oncology spinout deal, GSK's $1.0 billion siRNA deal with Frontier Biotechnologies, and Pfizer China's $495 million ecnoglutide commercialisation deal with Sciwind Biosciences anchored an exceptionally active licensing week. Protagonist Therapeutics' expected $400 million opt-out from its Takeda profit-sharing arrangement on rusfertide — converting a 50:50 US commercial partnership into 14–19% tiered royalties — adds another structurally significant royalty-creating event to the week.
The most structurally significant transaction for the royalty and non-dilutive financing market was the ADC Therapeutics / HealthCare Royalty amended royalty purchase agreement, which reduced the change-of-control payment from $750 million to $150–200 million in exchange for 9.8 million warrants — a deal structure that simultaneously eases M&A optionality for ADCT while providing HealthCare Royalty with equity upside participation. Immunic's $400 million private placement included an embedded 5% synthetic royalty on vidofludimus calcium created through a novel warrant-for-royalty exchange mechanism, demonstrating how synthetic royalty structures are being adapted for smaller biotech transactions.
Pfizer's option exercise on Beam Therapeutics' liver-targeted gene editing candidate and Beam's $500 million Sixth Street debt facility further demonstrated the growing importance of structured non-dilutive capital in late-stage biotech. Venture capital activity was concentrated in a single notable round — Slate Medicines' $130 million Series A for migraine therapeutics — while Generate:Biomedicines' $400 million Nasdaq IPO (the largest biotech IPO since 2024) and two HKEX main board filings (Tianchen Biopharmaceutical, Hanfang Pharmaceutical) underscored the reopening global biotech IPO window. BioMarin's Amicus stockholder vote (scheduled March 3) continued to advance the largest pending rare disease transaction.
On the royalty market intelligence front, two major earnings reports from the sector's largest public royalty aggregators provided a comprehensive view of the royalty financing landscape. Ligand Pharmaceuticals (February 26) reported FY2025 royalty revenue of $161 million (+48% YoY) and reiterated 2026 guidance of $200–225 million in royalty revenue with $1 billion+ in deployable capital, while Royalty Pharma (February 11, with TD Cowen conference presentation announced February 26) reported FY2025 Portfolio Receipts of $3.25 billion (+16% YoY) and guided 2026 Portfolio Receipts to $3.275–3.425 billion. Both companies emphasized the royalty funding market reaching a record $10 billion in 2025 and the increasing mainstreaming of royalty financing as a non-dilutive capital tool.
This report covers all material transactions globally across M&A, licensing, collaborations, royalty financing, debt, equity financings, and supply agreements from February 22 through February 27, 2026. Deals are organized by type, sorted by size within each section, and include financial terms, advisors, and source references where available. This edition also includes regional regulatory milestones (GSK's first-ever global NDA filing for bepirovirsen in Japan and linerixibat priority review acceptance in China) and an AI-in-drug-development licensing deal (Shionogi/Hitachi) sourced from Japanese- and Chinese-language primary sources.
Week at a Glance
| Category | Count | Total Value |
|---|---|---|
| M&A (announced) | 4 | ~$9.83B |
| Licensing & Collaborations | 9+ | ~$8.0B+ potential |
| Royalty Financing (amended + synthetic) | 2 | ADCT/HCR restructured ($300M original; new CoC terms); IMUX 5% synthetic royalty via warrant exchange |
| Royalty Market Intelligence | 2 earnings | LGND: $161M FY25 royalties; RPRX: $3.25B FY25 receipts |
| Royalty Fund Activity Tracker | 4 firms | LGND earnings (Feb 26); RPRX TD Cowen conference (Mar 3) + MIT Faculty Founder Initiative ($3M gift); HCRx/ADCT amendment; DRI earnings scheduled Mar 4 |
| Regional Regulatory Milestones | 2 | GSK: bepirovirsen NDA accepted Japan MHLW; linerixibat NDA priority review China NMPA |
| AI in Drug Development | 1 | Shionogi/Hitachi genAI regulatory-doc licence (Japan) |
| Debt / Non-Dilutive Capital | 1 | $500M |
| Option Exercises | 1 | Part of $1.35B original collaboration |
| Venture Capital | 1 | $130M |
| IPOs & Listing Filings | 3 | $400M (Generate:Biomedicines Nasdaq IPO) + 2 HKEX filings (Tianchen Bio, Hanfang Pharma) |
| Equity Offerings (reported in week) | 2 | $225M+ |
| Smaller Collaborations, Licensing & Radiopharmaceuticals | 15+ | Mixed / Undisclosed |
| Supply Agreements (CDMO) | 1 | $250M (5-year) |
Mergers and Acquisitions
Two M&A transactions were announced during the reporting period, with a third breaking on the final day of the week and a fourth — Novartis AG's divestiture of its India-listed subsidiary — closing out the M&A roster. The Gilead/Arcellx deal represents the largest oncology acquisition of 2026 to date and signals continued Big Pharma appetite for clinical-stage cell therapy platforms.
GSK's 35Pharma acquisition extends its respiratory and cardiovascular pipeline into the rapidly growing pulmonary hypertension market, where Merck's Winrevair generated $1.4 billion in 2025 sales.
Asahi Kasei's €780 million acquisition of Germany's Aicuris — executed through its US subsidiary Veloxis Pharmaceuticals — marks a significant cross-border infectious disease deal that brings immediate royalty income (Prevymis) alongside near-term commercial upside (pritelivir, FDA approval targeted 2026).
| Date | Acquirer | Target | Asset / Indication | Financial Terms | Stage | Advisors | Source |
|---|---|---|---|---|---|---|---|
| Feb 23 | Gilead Sciences | Arcellx (Nasdaq: ACLX) | Anito-cel (BCMA-directed CAR-T, multiple myeloma); D-Domain CAR platform | $115/share + $5 CVR (~$7.8B); 68% premium to 30-day VWAP | BLA filed (PDUFA Dec 23, 2026) | Gilead: BofA, Morgan Stanley, Ropes & Gray. Arcellx: Centerview Partners, Wilson Sonsini | Gilead PR |
| Feb 25 | GSK | 35Pharma Inc. (Canada, private) | HS235 (activin signaling inhibitor, pulmonary hypertension) | $950M cash at closing | Phase 1 complete (Ph2 imminent) | 35Pharma: Centerview Partners, J.P. Morgan; US legal: Cooley LLP; Canadian legal: Stikeman Elliott LLP | GSK PR, GlobeNewswire |
| Feb 26 | Asahi Kasei (via Veloxis Pharmaceuticals) | Aicuris Anti-infective Cures AG (Germany, private) | Prevymis (letermovir, CMV prevention, marketed via MSD royalty); pritelivir (HSV, Phase 3 complete); AIC468 (BKV, Phase 1 complete) | €780M (~$920M) cash | Marketed (royalty) / NDA-ready / Phase 1 | Aicuris: Bank of America, Gibson Dunn. Asahi Kasei: Freshfields | Manila Times, Endpoints |
| Feb 19 | ChrysCapital Fund X / WaveRise Investments / Two Infinity Partners (PE consortium) | Novartis India Limited (BSE-listed; 70.68% stake from Novartis AG) | Legacy portfolio: off-patent and branded generics in immunology, neuroscience, pain; 20+ commercial products | ₹14.46B (~$159M) for 70.68% stake; mandatory open offer for additional 26% at ₹860.64/share (~$61M); total implied enterprise value ~$225M | Marketed (commercial portfolio) | Acquirer: Axis Capital (open offer manager) | Novartis India PR, Bloomberg |
Gilead Sciences / Arcellx Acquisition (Announced February 23)
Gilead Sciences entered a definitive agreement to acquire Arcellx for $115 per share in cash plus one non-tradeable contingent value right (CVR) worth $5 per share, representing a total equity value of approximately $7.8 billion. The offer price reflects a 68% premium to Arcellx's 30-day volume-weighted average share price as of February 20, 2026, and a 79% premium to the February 20 closing price.
The transaction is structured as a tender offer followed by a second-step merger. Gilead currently owns approximately 11.5% of Arcellx's outstanding common stock through prior collaboration investments. The tender offer requires a majority of remaining shares to be tendered, with expected closing in Q2 2026 subject to HSR clearance and customary conditions.
The asset. Anitocabtagene autoleucel (anito-cel) is a BCMA-directed autologous CAR-T cell therapy for relapsed or refractory multiple myeloma. The therapy utilizes Arcellx's proprietary D-Domain synthetic binding technology, which generates target-binding domains with enhanced specificity compared to traditional single-chain variable fragment (scFv) approaches used in competing CAR-T products. Anito-cel's D-Domain binder is designed to provide more controlled BCMA engagement, potentially reducing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) — two dose-limiting toxicities that have constrained the commercial adoption of existing BCMA-targeting CAR-T therapies.
The BLA for anito-cel as a fourth-line treatment is supported by Phase 1 and the pivotal Phase 2 iMMagine1 trial, with FDA acceptance and a PDUFA target action date of December 23, 2026. The competitive context is critical: Johnson & Johnson/Legend Biotech's Carvykti generated approximately $1.9 billion in 2025 sales and has already secured second-line approval. Anito-cel's differentiation rests on its safety profile claims — data from clinical studies suggest a lower incidence of severe CRS and neurotoxicity compared to Carvykti.
The CVR is payable if cumulative global net sales of anito-cel reach at least $6 billion from launch through end of 2029 — a target that implies annualized peak sales of approximately $2 billion, ambitious but achievable if the drug secures earlier-line indications.
Beyond anito-cel, Arcellx brings the D-Domain CAR platform, early-stage programs in acute myeloid leukemia and generalized myasthenia gravis, and technology applicable to next-generation in vivo cell therapy — an area where Gilead's Kite Pharma division can leverage the D-domain BCMA binder for non-autologous approaches. The acquisition also eliminates up to $1.5 billion in potential milestone payments Gilead would have owed under the existing Kite/Arcellx collaboration, effectively converting variable future obligations into a fixed acquisition cost.
Advisors. Gilead financial: BofA Securities, Morgan Stanley. Gilead legal: Ropes & Gray LLP. Arcellx financial: Centerview Partners. Arcellx legal: Wilson Sonsini Goodrich & Rosati.
GSK / 35Pharma Acquisition (Announced February 25)
GSK entered a definitive agreement to acquire 35Pharma Inc., a Canada-based private clinical-stage biopharmaceutical company, for $950 million payable in cash at closing. The transaction is subject to HSR clearance in the United States, Competition Act clearance in Canada, and an Investment Canada Act filing.
The asset. HS235 is an activin signaling inhibitor — a protein therapeutic targeting the TGF-beta superfamily — that has completed Phase 1 healthy volunteer clinical trials with Phase 2 studies in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) set to begin imminently. HS235 is designed with enhanced selectivity to reduce binding to BMP9 and BMP10, ligands associated with adverse bleeding events and telangiectasia that have been observed with the first-generation activin signaling inhibitor sotatercept (Merck's Winrevair). Winrevair, approved for PAH in March 2024, generated $1.4 billion in 2025 sales and is forecast to reach $4–5 billion at peak. The global PH therapy market is projected to reach $18 billion by 2032, with activin signaling inhibitors expected to capture approximately half of that market.
The $950 million price for a Phase 1-complete asset reflects the validated mechanism (Winrevair's commercial success de-risks the target biology), the large addressable market (approximately 82 million people worldwide affected by PH across multiple forms), and the potential best-in-class profile through reduced BMP9/BMP10 binding.
GSK has been systematically building its respiratory and inflammation pipeline, and HS235's potential protective effects on vascular function alongside metabolic and anti-inflammatory benefits position it as a multi-indication platform asset within GSK's broader chronic disease strategy.
Advisors. 35Pharma financial: Centerview Partners LLC, J.P. Morgan Securities LLC. 35Pharma US legal: Cooley LLP. 35Pharma Canadian legal: Stikeman Elliott LLP.
Asahi Kasei / Aicuris Acquisition (Announced February 26)
Asahi Kasei entered a definitive agreement to acquire all issued shares of Aicuris Anti-infective Cures AG, a Wuppertal, Germany-based biopharmaceutical company, for approximately €780 million (~$920 million at $1/€0.85 as of February 25) in an all-cash transaction. The acquisition is being executed through Veloxis Pharmaceuticals, Asahi Kasei's US-based transplant therapeutics subsidiary (marketed product: Envarsus XR, tacrolimus for kidney transplant). The transaction is expected to close in H1 2026 subject to customary conditions, and Asahi Kasei expects the acquisition to contribute positively to operating income from fiscal 2028 onward.
The portfolio. Aicuris brings three complementary antiviral assets targeting immunocompromised patients:
(1) Prevymis (letermovir) — an approved cytomegalovirus (CMV) terminase inhibitor marketed globally by MSD (Merck). Aicuris originated the drug and retains royalty economics as the originator. Prevymis is the standard of care for CMV prevention in hematopoietic stem cell transplant recipients and generated significant ongoing royalty income for Aicuris.
(2) Pritelivir — a first-in-class herpes simplex virus (HSV) helicase-primase inhibitor that has completed Phase 3 clinical trials for treatment of HSV infections in immunocompromised patients. FDA approval is targeted for 2026. Pritelivir represents an entirely new oral mechanism of action for HSV — distinct from acyclovir-class drugs — addressing patients for whom current nucleoside analogues are insufficient, including acyclovir-resistant HSV infections that affect a growing population of transplant and immunosuppressed patients.
(3) AIC468 — an antisense oligonucleotide (ASO) targeting BK virus (BKV) in kidney transplant recipients, with Phase 1 complete and commercialization targeted for 2030. BKV nephropathy is a significant cause of renal allograft failure with no approved therapies, making this an uncontested market opportunity.
Strategic rationale. The acquisition aligns with Asahi Kasei's "One AK Pharma" operating model integrating a tri-regional (Japan, US, Europe) specialty pharmaceutical footprint across transplantation (Veloxis), nephrology (Calliditas), and now severe infectious diseases. The key synergy is channel overlap: pritelivir and AIC468 target patient populations (transplant recipients, immunocompromised) who are already managed in the same transplant centers and nephrology clinics where Veloxis and Calliditas have established commercial infrastructure. This shared customer base enables efficient market access without building a new salesforce. The layered revenue profile — immediate royalty income (Prevymis), near-term commercial launch (pritelivir), and longer-term pipeline (AIC468) — creates durable growth underpinning.
Advisors. Aicuris financial: Bank of America Europe DAC. Aicuris legal: Gibson Dunn. Asahi Kasei legal: Freshfields Bruckhaus Deringer.
Novartis AG / Novartis India Limited Divestiture (Announced February 19)
Novartis AG entered an agreement to sell its entire 70.68% stake in Novartis India Limited (BSE-listed) to a consortium of private equity firms — ChrysCapital Fund X, WaveRise Investments, and Two Infinity Partners — for approximately ₹14.46 billion (~$159 million). The transaction follows a strategic review initiated in February 2024 and is expected to close in Q3 2026. The PE consortium has also launched a mandatory open offer under SEBI takeover regulations to acquire up to an additional 26% of Novartis India shares from public shareholders at ₹860.64 per share, representing a potential further payout of approximately ₹552.5 crore (~$61 million). If fully subscribed, the acquirers' combined shareholding would reach 96.68%.
The business. Novartis India Limited is primarily engaged in wholesale distribution of pharmaceuticals and medical goods, marketing older and off-patent drugs across immunology, neuroscience, and pain. For FY2024–25, NIL reported revenue from operations of ₹356.27 crore and profit after tax of ₹100.90 crore — a profitable but low-growth commercial portfolio. The company will be required to remove all Novartis branding within 120 days of closing.
What remains in India. Novartis AG will continue operating Novartis Healthcare Private Limited (NHPL), its wholly owned Indian subsidiary that houses the innovative medicines commercial arm, a corporate center in Hyderabad employing over 9,000 associates, and R&D teams conducting clinical trials across 300+ sites. The NIL divestiture does not affect NHPL's business, workforce, or the expanding Cardio-Renal-Metabolic and Oncology portfolios in India.
Strategic context. The divestiture completes Novartis's transformation into a pure-play innovative medicines company, shedding the last major legacy generics subsidiary. ChrysCapital's existing healthcare portfolio includes Intas Pharmaceuticals, Eris Lifesciences, and Corona Remedies, suggesting the consortium will pursue portfolio rationalization and operational optimization under PE ownership — a familiar playbook for branded generics businesses in India. The deal also reflects a broader trend of multinational pharma companies divesting listed emerging market subsidiaries that are no longer strategically aligned with innovation-focused portfolios.
Advisors. Acquirer (open offer): Axis Capital.
Pending M&A: BioMarin / Amicus Therapeutics (Stockholder Vote March 3)
BioMarin reported Q4/FY2025 results on February 23, confirming the $4.8 billion Amicus Therapeutics acquisition remains on track for Q2 2026 closing, with the Amicus stockholder vote scheduled for March 3. BioMarin disclosed it has secured approximately $3.7 billion in non-convertible debt financing with favorable pricing across the capital structure. Pro forma, BioMarin's revenue guidance of approximately $3.2 billion in 2026 (excluding Amicus) would increase meaningfully upon closing given Amicus's Galafold and Pombiliti + Opfolda portfolio, which generated approximately $600 million in trailing four-quarter revenue.
Advisors. BioMarin financial: Morgan Stanley (sole arranger). BioMarin legal: Gibson, Dunn & Crutcher LLP. Amicus financial: Lazard. Amicus legal: Kirkland & Ellis LLP.
Strategic Collaborations and Licensing
The week's licensing activity was exceptionally active, featuring six transactions each exceeding $1 billion in total potential value. Astellas' $1.7 billion collaboration with Vir Biotechnology for a masked T-cell engager in prostate cancer was the largest licensing deal of the week by total potential value. Harbour BioMed's Solstice Oncology spinout continued the "NewCo" model trend for China-originated assets. Novo Nordisk's oral biologics platform deal, GSK's dual transactions (one acquisition, one license), and Pfizer's Beam option exercise rounded out a week that underscored the breadth of Big Pharma pipeline activity.
| Date | Licensee / Partner | Licensor / Partner | Asset / Indication | Financial Terms | Stage | Source |
|---|---|---|---|---|---|---|
| Feb 23 | Astellas Pharma | Vir Biotechnology (Nasdaq: VIR) | VIR-5500 (PSMAxCD3 dual-masked T-cell engager, prostate cancer) | $335M upfront/near-term ($240M cash + $75M equity at 50% premium + $20M near-term milestone); up to $1.37B milestones; 50/50 US profit split; tiered double-digit ex-US royalties (~$1.7B total). Vir financial: Lazard | Phase 1 | Vir IR, Fierce Biotech |
| Feb 25 | Novo Nordisk | Vivtex Corporation (Boston / Schlieren, Switzerland) | GI-ORIS oral biologics delivery platform (obesity, T2D, metabolic) | Upfront + research funding + up to $2.1B milestones; tiered royalties | Platform / Discovery | GlobeNewswire, BioPharma Dive |
| Feb 23 | Solstice Oncology (US NewCo) | Harbour BioMed (HK: 02142) | Porustobart / HBM4003 (anti-CTLA-4 HCAb, solid tumors) | $105M upfront ($50M cash + $5M near-term + $50M+ equity); up to $1.1B milestones; tiered royalties (~$1.2B total) | Phase 1 (multiple indications in China) | Fierce Biotech, BioSpace |
| Feb 24 | GSK | Frontier Biotechnologies Inc. (Nanjing, China) | Two siRNA candidates (kidney diseases, immunology) | $40M upfront; up to $963M milestones; tiered royalties (~$1.0B total) | IND / Preclinical | PR Newswire |
| Feb 24 | Pfizer | Beam Therapeutics | Liver-targeted in vivo base editing candidate (rare genetic liver disease) | Option exercised from $300M upfront / $1.35B total 2021 collaboration; 35/65 profit split post-Ph1/2 | Preclinical | Fierce Biotech, GlobeNewswire |
| Feb 25 | Vanda Pharmaceuticals | AnaptysBio (Nasdaq: ANAB) | Imsidolimab (anti-IL-36R, Generalized Pustular Psoriasis) — BLA accepted, PDUFA Dec 12, 2026 | $10M upfront + $5M drug supply; up to $35M milestones; 10% royalty on global net sales | Registration (BLA accepted) | PR Newswire, AnaptysBio IR |
| Feb 25 | Viatris Inc. | Opus Genetics | MR-141 (Phentolamine Ophthalmic Solution 0.75%, Presbyopia) | Undisclosed | Registration | Opus Genetics |
| Feb 25 | Cumberland Pharmaceuticals | RedHill Biopharma | Talicia® (H. pylori infection) | Undisclosed (collaboration) | Approved | Cumberland Pharma |
| Feb 24 | Pfizer China | Hangzhou Sciwind Biosciences (China) | Ecnoglutide injection (cAMP-biased GLP-1 RA, T2D approved / obesity under NMPA review) | Up to $495M (upfront + regulatory + sales milestones); Pfizer exclusive commercialisation rights in Mainland China; Sciwind retains MAH, R&D, manufacturing, supply | Approved (T2D, Jan 2026) / Registration (obesity) | PR Newswire |
| Feb 24 | Almirall | etherna | LAD116 (non-melanoma skin cancer) | Undisclosed | Preclinical | Almirall |
| Feb 24 | Clinect Pty Ltd | Grünenthal | Qutenza® (peripheral neuropathic pain) | Undisclosed (licensing) | Marketed | Grünenthal |
| Feb 27 | Earendil Labs (US) | WuXi XDC Cayman (HK: 2268) | WuXiTecan-2 payload-linker platform (ADC, multiple oncology targets) | Upfront + up to $885M milestones; tiered royalties; exclusive global license + CMC support | Discovery / Preclinical | PR Newswire (Earendil), PR Newswire (WuXi XDC) |
| Feb 27 | Asieris Pharmaceuticals (SSE: 688176) | Photocure ASA (OSE: PHO) | Cevira / APL-1702 (photodynamic therapy, HSIL; EMA MAA accepted) | $5M signing fee + up to $54M milestones; royalties (original 2019 license) | Registration (MAA accepted) | PR Newswire |
| Feb 27 | Eli Lilly (NYSE: LLY) | Incyte (Nasdaq: INCY) | Olumiant / baricitinib (severe alopecia areata, adolescents 12–<18; CHMP positive opinion) | Original 2009 license; Incyte royalties on global sales | Registration (CHMP positive opinion; EC decision Q2 2026) | PR Newswire |
| Feb 27 | Norgine B.V. | X4 Pharmaceuticals (Nasdaq: XFOR) | XOLREMDI / mavorixafor (WHIM syndrome; CHMP positive opinion) | €28.5M upfront + up to €226M milestones; escalating double-digit royalties to mid-20s% (Jan 2025 license) | Registration (CHMP positive opinion; EC decision Q2 2026) | PR Newswire, GlobeNewswire |
| Feb 25 | Takeda Pharmaceuticals (sole licensee post opt-out) | Protagonist Therapeutics (Nasdaq: PTGX) | Rusfertide (injectable hepcidin mimetic, polycythemia vera); profit-sharing restructuring | $400M opt-out payments + enhanced milestones + 14–19% tiered royalties on worldwide net sales (replacing 50:50 US profit split from Jan 2024 $300M license) | NDA filed (FDA decision expected 2026) | Fierce Biotech, Newswire |
Norgine / X4 Pharmaceuticals — Mavorixafor CHMP Positive Opinion (Feb 27). The EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorisation under exceptional circumstances for mavorixafor (XOLREMDI) for the treatment of WHIM syndrome, an ultra-rare primary immunodeficiency affecting approximately 1,000 patients worldwide.
Mavorixafor is an oral, once-daily selective CXCR4 antagonist and the first approved therapy for WHIM syndrome in the US (April 2024). The CHMP opinion was supported by the 4WHIM Phase 3 trial (n=31), which showed statistically significant improvement in absolute neutrophil and lymphocyte counts versus placebo (p<0.0001), approximately 40% reduction in total infection score, and 60% reduction in annualized infection rate.
Norgine (~$650M annual sales) holds exclusive commercialisation rights in Europe, Australia, and New Zealand under a January 2025 license (€28.5M upfront + up to €226M milestones + escalating royalties to mid-20s%). X4 retains manufacturing and supply responsibilities. EC decision expected Q2 2026.
Astellas / Vir Biotechnology Global Collaboration for VIR-5500 (Announced February 23)
Astellas Pharma and Vir Biotechnology entered a global strategic collaboration to co-develop and co-commercialize VIR-5500, a dual-masked T-cell engager (TCE) targeting prostate-specific membrane antigen (PSMA) for the treatment of prostate cancer. Vir Biotechnology will receive $335 million in upfront and near-term payments comprising $240 million in cash, a $75 million equity investment at a 50% premium to 30-day VWAP, and a $20 million near-term milestone. The deal includes up to $1.37 billion in additional development, regulatory, and sales milestones, plus tiered double-digit royalties on ex-US net sales — a total potential value exceeding $1.7 billion. Global development costs will be shared 60% Astellas / 40% Vir. In the US, Vir retains co-promotion rights with a 50/50 profit and loss split. Astellas has exclusive commercialization rights outside the US.
The asset. VIR-5500 is a PSMAxCD3 bispecific TCE built on the PRO-XTEN dual-masking platform, which Vir licensed from Sanofi in 2024 (via Sanofi's acquisition of Amunix Pharmaceuticals). The PRO-XTEN technology keeps the TCE inactive until it reaches the tumor microenvironment, where tumor-associated proteases cleave the masking domains to activate T-cell engagement — a conditional activation design intended to improve the therapeutic index by reducing systemic cytokine release and off-target T-cell activation.
Updated Phase 1 data presented at ASCO GU 2026 from 58 patients receiving VIR-5500 monotherapy demonstrated promising efficacy: among 17 PSA-evaluable patients dosed at 3,000–4,000 µg/kg Q3W, 82% achieved PSA50 declines, 53% achieved PSA90 declines, and 45% of 11 RECIST-evaluable patients showed objective tumor responses. Safety was favorable with limited high-grade cytokine release syndrome (CRS) and no dose-limiting toxicities — differentiating VIR-5500 from unmasked TCEs like Johnson & Johnson's teclistamab, which carry higher CRS burden. Vir plans to initiate pivotal Phase 3 trials in 2027 and is opening Phase 1 dose-expansion cohorts in metastatic hormone-sensitive prostate cancer (mHSPC) in Q2 2026.
Strategic context. For Astellas, this deal deepens its prostate cancer franchise built around Xtandi (enzalutamide, approximately $6 billion in cumulative sales), adding a next-generation immunotherapy mechanism to complement androgen receptor pathway inhibitors. The 60/40 cost share reflects Astellas' larger infrastructure commitment while Vir's co-promote option preserves its participation in US commercial upside.
The collaboration agreement was signed on February 19, 2026 (per the 8-K), with Astellas purchasing 7,239,382 shares of Vir common stock at $10.36 per share (50% premium to 30-day VWAP) under a separate stock purchase agreement with one-year standstill, voting, and lock-up provisions.
Truist Securities described VIR-5500 as a "robust competitor" in the PSMA-targeting space, noting the masking technology enables higher dosing than competing unmasked agents. The competitive field includes Janux Therapeutics' JANX007 (Phase 1, ahead of VIR-5500 in development), Amgen's xaluritamig (STEAP1-targeting), and Novartis' Pluvicto (radioligand therapy). Sanofi will receive a portion of collaboration proceeds under Vir's original PRO-XTEN licensing agreement. Vir shares rose nearly 30% on the announcement.
Advisors. Vir Biotechnology financial: Lazard (exclusive financial advisor).
Harbour BioMed / Solstice Oncology Anti-CTLA-4 Deal (Announced February 23)
Shanghai-based Harbour BioMed co-founded Solstice Oncology, a Cambridge, Massachusetts-based biotech, and granted it exclusive worldwide rights (excluding Greater China) to porustobart (HBM4003), a next-generation fully human anti-CTLA-4 monoclonal heavy chain-only antibody (HCAb). Harbour will receive $105 million in upfront consideration — $50 million in cash, $5 million in near-term payments, and more than $50 million in equity in Solstice — plus up to approximately $1.1 billion in development, regulatory, and commercial milestone payments, and tiered royalties on ex-Greater China net sales. Total potential deal value exceeds $1.2 billion.
The asset. Porustobart was developed using Harbour's proprietary Harbour Mice platform, which generates fully human heavy chain-only antibodies. It is the first fully human HCAb to enter clinical development globally. The molecule is designed to enhance regulatory T-cell (Treg) depletion within the tumor microenvironment through optimized Fc engineering while reducing the systemic autoimmune toxicity that has limited the clinical utility of first-generation CTLA-4 inhibitors like Bristol Myers Squibb's Yervoy (ipilimumab). In China, Harbour has been running mid-stage clinical trials across melanoma, microsatellite-stable colorectal cancer (MSS-CRC), hepatocellular carcinoma, and neuroendocrine tumors.
Combination data from 23 MSS-CRC patients treated with porustobart plus BeOne Medicines' PD-1 inhibitor Tevimbra showed a 35% overall response rate — notable for an indication historically resistant to checkpoint inhibitors — though treatment-related serious adverse events were observed in 38% of patients, consistent with the CTLA-4 mechanism.
NewCo model. The deal exemplifies the increasingly common "NewCo" licensing structure for China-originated biotech assets, in which the Chinese originator retains equity participation in a newly formed Western company rather than executing a conventional arms-length license. Solstice Oncology was incorporated in the UK earlier in February 2026 and is backed by a syndicate of unnamed major venture capital investors.
By taking a $50 million+ equity stake in Solstice, Harbour participates in the global value creation of porustobart while sharing development risk with its venture capital co-founders. The structure also positions Harbour to benefit from any eventual M&A exit of Solstice.
The CTLA-4 space remains active: BioNTech is advancing its licensed ONC-392 (from OncoC4) in Phase 3, while MacroGenics' lorigerlimab (PD-1xCTLA-4 bispecific) faces setbacks including a recent partial clinical hold on its Phase 2 Linnet study in gynecologic cancers. At least 24 anti-CTLA-4 monoclonal antibodies are currently in clinical development globally.
Novo Nordisk / Vivtex Oral Biologics Collaboration (Announced February 25)
Novo Nordisk and Vivtex Corporation announced a partnership to develop next-generation oral biologic medicines for obesity, diabetes, and associated comorbidities. Vivtex will license select oral drug-delivery technologies to Novo Nordisk and is eligible to receive upfront consideration, research funding, and milestone payments totaling up to $2.1 billion, plus tiered royalties on future product sales. Upfront cash was not disclosed.
Vivtex was founded by MIT scientists Robert Langer, Giovanni Traverso, and Thomas von Erlach in 2018. The company's GI-ORIS platform combines robotics-driven high-throughput gastrointestinal screening assays with computational simulation and AI-enabled analytics to optimize oral delivery of biologic medicines. The platform is designed to screen thousands of formulations per day and has demonstrated near-perfect correlation with human intestinal absorption outcomes — substantially outperforming conventional in vitro dissolution models.
The strategic context is significant. Novo Nordisk brought the first oral biologic (Rybelsus for diabetes) to market in 2019 and secured FDA approval for oral Wegovy (semaglutide for obesity) in late 2025. However, oral semaglutide faces bioavailability constraints that limit dose optimization.
The Vivtex collaboration aims to enable next-generation oral peptide and protein therapeutics with improved absorption, consistency, and patient convenience — addressing a structural limitation of current GLP-1 receptor agonist formulations. The $2.1 billion potential deal value positions this as one of the largest oral drug-delivery platform deals in industry history. Following research and formulation selection, Novo Nordisk assumes responsibility for all global development, regulatory, manufacturing, and commercialization activities.
GSK / Frontier Biotechnologies siRNA License (Announced February 24)
GSK secured exclusive worldwide rights to develop, manufacture, and commercialize two siRNA candidates from Nanjing-based Frontier Biotechnologies. The deal includes $40 million upfront and up to $963 million in development, regulatory, and commercial milestones, plus tiered royalties on worldwide net sales. Both candidates target kidney diseases driven by inflammation — one is at IND stage and the other is preclinical.
Frontier will initially advance both assets: conducting a Phase 1 clinical trial in China for the IND-enabled candidate and completing IND-enabling activities for the preclinical candidate. GSK assumes responsibility for all subsequent global clinical development, regulatory submissions, and commercialization.
This is GSK's second major siRNA licensing deal in recent months, following its $745 million pact with California-based Empirico for EMP-012, a clinical-stage COPD siRNA. The company has been systematically building an oligonucleotide portfolio that also includes collaborations with Arrowhead Pharmaceuticals (fatty liver disease), assets acquired from Wave Life Sciences, and a nonexclusive license to Elsie Biotechnologies' platform. The 24:1 milestone-to-upfront ratio is consistent with early-stage China-to-West licensing structures, where the Chinese partner retains early development risk and the global partner pays for de-risked advancement. Frontier's CEO Dong Xie described the deal as reflecting growing international recognition of the company's siRNA discovery and development capabilities.
Pfizer China / Sciwind Biosciences Ecnoglutide Commercialisation (Announced February 24)
Pfizer China secured exclusive commercialisation rights in Mainland China for ecnoglutide injection, a new-generation cAMP-biased GLP-1 receptor agonist developed by Hangzhou Sciwind Biosciences. Sciwind is eligible to receive up to $495 million in upfront, regulatory, and sales milestone payments. Sciwind retains its role as Marketing Authorization Holder and remains responsible for research and development, registration, manufacturing, and supply. The upfront payment amount was not disclosed.
The asset. Ecnoglutide was approved by China's NMPA in January 2026 for the treatment of adult type 2 diabetes, and its marketing authorisation application for adult chronic weight management has been accepted for NMPA review. The molecule's biased signaling mechanism — selectively activating cAMP pathways over β-arrestin — is designed to improve the therapeutic index relative to balanced GLP-1 agonists. In Chinese clinical studies, ecnoglutide demonstrated 15.1% placebo-adjusted weight loss, with 92.8% of patients achieving clinically meaningful weight reduction and over 80% attaining HbA1c levels below 7.0%.
Strategic context. The deal is contextually significant alongside this week's Novo Nordisk/Vivtex $2.1 billion oral biologics collaboration and Cipla's generic Saxenda US launch. Pfizer has been systematically building a GLP-1 franchise: the Sciwind deal follows its December 2025 acquisition of Metsera (next-generation obesity pipeline) and a recent global licensing agreement with YaoPharma.
In China specifically, obesity prevalence among adults is 14.1% and rising, with "healthy weight management" now officially incorporated into the national Healthy China Initiative. Ecnoglutide will not be included under China's state-run health insurance scheme for T2D, positioning it as a premium self-pay product — a commercial model that aligns with the broader GLP-1 market's transition toward cash-pay weight management indications. The deal adds a fourth China-originated licensing transaction to the week (alongside GSK/Frontier, Harbour/Solstice, and the DartsBio-originated Slate Medicines Series A), reinforcing the accelerating China-to-West and West-into-China asset flow across deal structures.
Pfizer / Beam Therapeutics Option Exercise (Disclosed February 24)
Pfizer exercised its option under the December 2021 research collaboration agreement ($300 million upfront, up to $1.35 billion total) for global rights to a liver-targeted in vivo base editing candidate using Beam's proprietary lipid nanoparticle (LNP) delivery technology. The undisclosed asset targets a rare genetic liver disease.
Pfizer assumes full responsibility for development activities, manufacturing, and potential commercialization. Beam will be eligible for development, regulatory, and commercial milestone payments and retains an opt-in right at the end of Phase 1/2 clinical trials. If exercised, Beam and Pfizer would share net profits and costs in a 35%/65% ratio (Beam/Pfizer) — a co-development structure that gives Beam meaningful economic participation while shifting the majority of execution risk and capital requirements to Pfizer.
The option exercise is strategically notable because it follows Pfizer's exit from gene therapy in February 2025, when it discontinued hemophilia product Beqvez less than a year after FDA approval. Rather than abandoning genetic medicine entirely, Pfizer is pivoting from gene replacement therapy (adeno-associated virus delivery) to gene editing (base editing with LNP delivery) — a modality shift that reflects the industry's broader recognition that in vivo editing approaches may offer superior durability and manufacturing scalability compared to AAV-based gene therapy.
Protagonist Therapeutics / Takeda Rusfertide Opt-Out (Disclosed February 25)
Protagonist Therapeutics disclosed in its Q4/FY2025 earnings release that it currently expects to exercise its opt-out right from the 50:50 US profit and loss sharing arrangement with Takeda Pharmaceuticals for rusfertide in Q2 2026. Under the January 2024 worldwide license and collaboration agreement ($300 million upfront), Protagonist has a 90-day opt-out window that opens 120 days after filing of the rusfertide NDA with the FDA — which was submitted in early January 2026.
The restructured economics. By opting out, Protagonist will forgo the 50:50 US profit split and instead receive opt-out payments of up to $400 million, enhanced milestone payments, and 14–19% tiered royalties on worldwide net sales of rusfertide. This restructuring transforms Protagonist's economic interest from an active co-commercialization partner bearing 50% of US commercial costs into a pure royalty recipient — a structural shift that significantly de-risks the company's P&L while preserving meaningful economic upside through double-digit royalties on what is expected to be a first-in-class therapy for polycythemia vera.
The asset. Rusfertide is a first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production in patients with polycythemia vera (PV), a rare chronic myeloproliferative neoplasm. In the pivotal Phase 3 VERIFY trial, rusfertide met its primary endpoint and all four key secondary endpoints, demonstrating sustained hematocrit control with reduced phlebotomy burden and improved symptom management versus standard of care alone. Rusfertide has received Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation from the FDA. An FDA decision is anticipated in 2026.
Royalty financing context. The opt-out decision is structurally significant for the royalty financing market. Protagonist is effectively self-creating a royalty stream — converting an equity-like profit-sharing position into a fixed royalty interest. With $646 million in cash at year-end 2025, Protagonist has the balance sheet to fund its wholly owned pipeline (including PN-881, PN-477 oral triple GLP-GIP-GCG agonist, and PN-458 oral dual GLP-GIP agonist) without the commercial infrastructure costs of co-promoting rusfertide.
For royalty investors, this deal illustrates how biotech companies are increasingly choosing royalty economics over profit-sharing structures — voluntarily converting active commercial participation into passive income streams. The 14–19% tiered royalty rate on a potential blockbuster rare disease product (PV prevalence ~44–57 per 100,000 in the US, with limited effective therapies) represents a high-quality, long-duration cash flow. Barclays raised its price target to $113 following the earnings release, reflecting the financial clarity the opt-out provides.
BMS / SystImmune Izalontamab Brengitecan Phase 3 TNBC Readout (Announced February 26)
SystImmune and Bristol Myers Squibb announced positive topline results from a pre-specified interim analysis of the Phase III BL-B01D1-307 trial evaluating izalontamab brengitecan (iza-bren) in patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose disease progressed following prior taxane therapy. The study met both dual primary endpoints of progression-free survival (PFS) and overall survival (OS) versus chemotherapy of physician's choice — a notably rigorous bar for a post-taxane TNBC population. This is the third Phase III study in which iza-bren has achieved its primary endpoint(s).
The deal context. BMS licensed iza-bren from SystImmune (a subsidiary of China's Sichuan Biokin Pharmaceutical) in December 2023 for $800 million upfront plus up to $500 million in contingent near-term payments and up to $7.1 billion in development, regulatory, and sales milestones — a total potential deal value of $8.4 billion. In October 2025, BMS paid a $250 million milestone upon first patient dosing in the global Phase 2/3 IZABRIGHT-Breast01 registrational study. Outside of China, iza-bren is jointly developed by SystImmune and BMS; SystImmune's parent Biokin retains exclusive China rights.
The asset. Iza-bren is a potentially first-in-class bispecific ADC targeting both EGFR and HER3 — two receptors highly expressed across multiple epithelial cancers — with a novel topoisomerase I inhibitor payload. The dual-targeting mechanism is designed to block compensatory signaling pathways that drive resistance to single-target EGFR therapies. Iza-bren has received Breakthrough Therapy Designation from both China's CDE (for seven indications) and the US FDA (for previously treated EGFR-mutant NSCLC). NDAs for nasopharyngeal carcinoma and esophageal squamous cell carcinoma have been accepted for priority review in China.
Strategic significance. The TNBC Phase 3 success is significant for three reasons. First, it further validates the bispecific ADC platform as a next-generation oncology modality, adding to the competitive field against Gilead's Trodelvy (Trop-2 ADC, the current standard in post-taxane TNBC) and AstraZeneca/Daiichi Sankyo's Enhertu (HER2-directed ADC). Second, it adds another major China-originated asset that has demonstrated clinical success — reinforcing the week's broader theme of accelerating China-to-West asset flow. Third, the achievement of an OS endpoint at interim analysis in TNBC is particularly notable in a treatment setting where durable survival gains have historically been limited. Full data will be presented at an upcoming medical meeting.
Royalty Financing
The week produced two structurally significant royalty transactions: the ADC Therapeutics / HealthCare Royalty amendment (restructuring an existing royalty to enable M&A optionality) and the Immunic synthetic royalty embedded within a $400 million private placement (creating a new royalty obligation via warrant exchange). Both merit detailed analysis for the royalty financing market.
| Date | Company | Royalty Partner | Product | Terms | Source |
|---|---|---|---|---|---|
| Feb 23 | ADC Therapeutics (NYSE: ADCT) | HealthCare Royalty | ZYNLONTA® (loncastuximab tesirine, CD19-directed ADC, r/r DLBCL) | CoC payment reduced from $750M to $150M (through 2027) / $200M (thereafter); HCR granted warrants for 9.8M shares at $3.81; royalty buyout: $525M (pre-2029) / $750M (post-2029) less prior payments; original 7% royalty continues to cap | PR Newswire |
| Feb 12–17 (closed W09) | Immunic, Inc. (Nasdaq: IMUX) | BVF Partners + Series B Warrant holders | Vidofludimus calcium (MS, oral DHODH/Nurr1, Phase 3) | 5% synthetic royalty on global net sales created via Royalty Purchase Agreement; 51,087,000 May 2025 Series B Warrants exchanged for pro rata royalty participation; payable quarterly post-first commercial sale; embedded within $200M upfront / $400M total private placement | PR Newswire |
ADC Therapeutics / HealthCare Royalty Amended Agreement (Announced February 23)
ADC Therapeutics amended its royalty purchase agreement with HealthCare Royalty, which originally provided $300 million in non-dilutive capital in 2021 (comprising $225 million at closing plus $75 million on EU commercial launch) in exchange for a 7% royalty on worldwide ZYNLONTA net sales (capped at 2.25x–2.50x of total consideration paid) and a 7% royalty on Cami (camidanlumab tesirine) net sales.
Key amended terms:
The change-of-control (CoC) payment was reduced from $750 million to $150 million if a CoC occurs through the end of 2027, and $200 million if thereafter. In a CoC scenario, HealthCare Royalty continues to receive royalties on acquirer sales until the original royalty cap is reached. Alternatively, the acquirer (or ADCT successor) may buy out remaining royalty obligations by paying $525 million (if before December 31, 2029) or $750 million (if after January 1, 2030), less cumulative royalties previously paid and the CoC payment.
In exchange for the reduced CoC payment, HealthCare Royalty received warrants to purchase approximately 9.8 million common shares at an exercise price of $3.81 per share (near market at time of amendment), exercisable until December 31, 2030, with a lock-up through year-end 2027.
Structural significance. This amendment is a textbook example of how royalty agreements are restructured to accommodate changing corporate strategic priorities. ADCT's stated potential US peak revenue of $600 million to $1 billion for ZYNLONTA (assuming compendia inclusion and regulatory approval in earlier lines) makes the company a plausible M&A target.
The original $750 million CoC payment would have deterred potential acquirers or significantly reduced acquisition premiums — a value-destructive outcome for both ADCT shareholders and, ultimately, HealthCare Royalty (since a higher acquisition price indirectly supports the royalty asset's commercial trajectory). By reducing the CoC barrier to $150–200 million while preserving ongoing royalty streams and adding equity upside through warrants, both parties created a more M&A-friendly capital structure without materially changing the economic NPV of the royalty position.
Original deal advisors (2021). ADCT: Morgan Stanley (sole structuring agent), Ropes & Gray LLP, Davis Polk LLP. HealthCare Royalty: Gibson Dunn LLP.
Immunic Synthetic Royalty on Vidofludimus Calcium (Closed February 17)
Immunic created a 5% synthetic royalty on future worldwide net sales of vidofludimus calcium as part of a broader $400 million private placement announced February 12 and closed February 17, 2026. The synthetic royalty was structured through a separate Royalty Purchase Agreement under which holders of 51,087,000 Series B Warrants (originally issued in Immunic's May 2025 $65 million public offering at a combined price of $0.7499 per unit) exchanged those warrants for a pro rata share of an aggregate 5% royalty on future net sales of vidofludimus calcium. Each holder's royalty share equals the number of warrants exchanged divided by the total warrants exchanged, with royalties payable quarterly after first commercial sale.
The concurrent equity raise comprised 229,076,000 pre-funded warrants at $0.873 per warrant ($200 million upfront), with matching common warrants exercisable at $0.873 that could yield an additional $200 million. The common warrants expire 30 days after ENSURE Phase 3 data or February 17, 2031, whichever is earlier. BVF Partners L.P. led the placement and holds approximately 9.99% beneficial ownership post-transaction, with participation from RA Capital Management, OrbiMed, Janus Henderson Investors, EcoR1 Capital, Aberdeen Investments, Avidity Partners, Coastlands Capital, TCGX, Trails Edge Capital Partners, Vivo Capital, and Woodline Partners LP. Leerink Partners served as lead placement agent, with Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities, and Brookline Capital Markets as additional agents.
Structural significance for the royalty market. The Immunic synthetic royalty is notable for several reasons. First, it demonstrates the use of synthetic royalties at the micro-cap level — vidofludimus calcium is a Phase 3 asset at a company with a ~$250 million market cap, far smaller than the typical synthetic royalty deals seen from Royalty Pharma ($275M–$2B range) or HealthCare Royalty. Second, the warrant-for-royalty exchange mechanism is an innovative capital structure tool: by converting equity-like instruments (warrants) into product-linked cash flows (royalties), Immunic simultaneously reduced its dilutive overhang (cancelling 51M warrants) while creating an aligned investor base that benefits directly from commercial success.
Third, the 5% royalty rate is relatively modest compared to typical synthetic royalty financings (which often range from 4–10% depending on stage and risk), suggesting the warrant holders accepted lower royalty economics in exchange for eliminating the exercise-price risk inherent in the warrants. For the royalty investor community, this transaction illustrates how synthetic royalty mechanics are being adapted beyond the traditional "investor provides cash in exchange for royalty" paradigm into more creative equity-for-royalty swap structures.
About the asset. Vidofludimus calcium (IMU-838) is an oral, once-daily small molecule combining selective dihydroorotate dehydrogenase (DHODH) inhibition with first-in-class nuclear receptor-related 1 (Nurr1) activation — a dual mechanism designed to address both the inflammatory and neurodegenerative components of multiple sclerosis. The Phase 3 ENSURE trials in relapsing MS are expected to deliver top-line data by year-end 2026, with NDA submission targeted for mid-2027 and potential approval in 2028. Immunic is also initiating a Phase 3 programme in primary progressive MS (PPMS) in late 2026, estimated to take 3.5–4 years. Immunic originally acquired vidofludimus calcium from 4SC AG in 2016 and settled the original 4.4% royalty obligation to 4SC for $17.25 million (50% cash / 50% stock) in March 2021 — meaning the 5% synthetic royalty now represents the only royalty burden on the asset.
Royalty Market Intelligence
Two of the pharmaceutical royalty sector's most prominent public companies reported earnings during the week, providing a comprehensive read on the state of royalty financing, portfolio performance, and forward outlook. Taken together, these results confirm that the royalty funding market has entered a structural growth phase, with record capital deployment, expanding deal flow, and rising institutional adoption of royalties as a mainstream non-dilutive capital tool.
Ligand Pharmaceuticals Q4/FY2025 Earnings (Reported February 26)
Ligand Pharmaceuticals reported Q4 and full-year 2025 financial results that significantly exceeded expectations, underscoring the compounding power of a diversified royalty aggregation model.
Financial highlights. Q4 2025 revenue was $59.7 million (+39% YoY), with royalty revenue of $50.5 million (+45% YoY) as the primary growth driver. Non-GAAP adjusted EPS of $2.02 beat consensus of $1.46 by 38%. For the full year, total GAAP revenue was $268.1 million (vs. $167.1 million in 2024), with royalty revenue of $161.0 million (+48% YoY) and core adjusted diluted EPS of $8.13 (+42% YoY). GAAP net income was $124.5 million. Ligand ended 2025 with $733.5 million in cash, cash equivalents, and short-term investments, and management noted total deployable capital exceeding $1 billion when including equity holdings in Pelthos Therapeutics and available credit facility capacity.
2026 guidance reiterated. Ligand expects royalty revenue of $200–225 million (~32% growth at midpoint), Captisol revenue of $35–40 million, and contract revenue of $10–20 million, for total revenue of $245–285 million and adjusted EPS of $8.00–$9.00. These figures were first introduced at the December 2025 Investor Day. The EPS guidance of $8.00–$9.00 compared to prior Street consensus of approximately $4.85 at the time — nearly double the market's expectations. 2026 royalty growth is expected to be driven primarily by Filspari (sparsentan, IgA nephropathy/FSGS), Ohtuvayre (ensifentrine, COPD), Capvaxive (pneumococcal vaccine), and Zelsuvmi (berdazimer, molluscum contagiosum).
Key portfolio and pipeline updates:
- Filspari (Travere Therapeutics): Q4 2025 US net sales of $103 million (+108% YoY); global sales of approximately $355 million in FY2025, generating $32 million in Ligand royalties. PDUFA for supplemental FSGS indication: April 13, 2026.
- Qtorin rapamycin (Palvella Therapeutics): Positive Phase 3 SELVA study results announced February 24 for microcystic lymphatic malformations (MLM) — met primary endpoint with statistically significant improvement on the Microcystic LM Investigator Global Assessment, achieved significance on all secondary endpoints, with no drug-related SAEs. 98% of participants elected to continue treatment. NDA submission planned H2 2026. Ligand holds an 8–9.8% royalty; peak sales estimates range from $1–3 billion across multiple rare dermatological indications.
- Lasofoxifene (LeonaBio, formerly Athira Pharma): Phase 3 ELAINE-3 trial in ER+/HER2- metastatic breast cancer with ESR1 mutation >50% enrolled, data expected mid-2027. Ligand holds a tiered 6–10% royalty. LeonaBio acquired development rights in December 2025 alongside a $90 million PIPE.
- Ohtuvayre (ensifentrine, Verona Pharma via Nuance Pharma): NMPA of China accepted NDA for COPD maintenance treatment (January 2026).
Strategic commentary. CEO Todd Davis characterized 2025 as "a defining year" and emphasized that royalty financing has become a more mainstream capital tool, noting a doubling of the royalty funding market over five years. VP of Portfolio Strategy Lauren Hay described a new systematic portfolio management process aimed at increasing partner engagement and proactively identifying investment opportunities. Ligand's long-term targets project a royalty receipts CAGR of 23% through 2030, with total core revenue exceeding $400 million and adjusted EPS surpassing $13.50 by 2030.
Analyst reaction. HC Wainwright raised its price target from $231 to $239 (Buy). Citi initiated coverage in December 2025 with a Buy rating and $270 target. Despite the earnings beat, shares dipped ~6.6% in pre-market trading on February 27, potentially reflecting valuation concerns at the stock's current 77x P/E multiple.
Royalty Pharma Q4/FY2025 Earnings and Business Update (Reported February 11; Conference Announced February 26)
Royalty Pharma reported Q4 and full-year 2025 results on February 11 and on February 26 announced a fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3, 2026 — the next catalyst for potential deal commentary.
Financial highlights. Q4 2025 Portfolio Receipts of $874 million (+18% YoY); full-year Portfolio Receipts of $3,254 million (+16% YoY). Royalty Receipts grew 17% in Q4 and 13% for the full year to $3,127 million, driven primarily by Voranigo, Trelegy, Tremfya, and the cystic fibrosis franchise (Trikafta/Alyftrek). Net cash from operations was $827 million in Q4.
Capital deployment and shareholder returns. Royalty Pharma deployed $2.6 billion on royalty transactions in 2025, adding royalties on nine therapies, including the landmark $2 billion Revolution Medicines partnership (synthetic royalty on daraxonrasib + senior secured loan). Announced transactions totaled $4.7 billion, representing approximately 40% market share of the $10 billion royalty funding market. The company repurchased 37 million Class A shares for $1.2 billion and increased its quarterly dividend 7% to $0.235 per share ($0.94 annualized).
2026 guidance. Portfolio Receipts expected between $3,275–3,425 million, including Royalty Receipts growth of 3–8%. Operating and professional costs expected to decrease as a percentage of Portfolio Receipts due to extinguishing the management fee following the May 2025 internalization of the external manager (cumulative savings expected to exceed $1.6 billion over ten years). Interest payments estimated at $350–360 million.
Key 2026 catalysts. Multiple pivotal readouts anticipated: daraxonrasib (Revolution Medicines, pancreatic cancer), pelacarsen (Novartis/Arrowhead, cardiovascular), litifilimab (Biogen, lupus). FDA approval expected for zidesamtinib (Nuvalent, ROS1+ NSCLC, PDUFA September 18, 2026). Late-stage pipeline peak sales potential exceeds $43 billion, which management estimates could translate to greater than $2.1 billion annually in new royalties. Stock hit a 52-week high of $46.14 in late February.
Analyst reaction. Goldman Sachs raised price target from $45 to $51 (February 12). Morgan Stanley raised from $56 to $61. UBS upgraded to Buy with a $49 target (January 30). Consensus rating: Moderate Buy, average target $47.50.
Royalty Market Context
The Ligand and Royalty Pharma earnings reports, combined with the ADC Therapeutics / HealthCare Royalty restructuring and the Immunic synthetic royalty covered earlier in this report, collectively paint a picture of a maturing and expanding royalty financing ecosystem:
Record market size. The royalty funding market reached $10 billion in announced transactions in 2025, driven by the rise of synthetic royalties — structures where no pre-existing royalty obligation exists and the financing creates a new royalty stream tied to future product sales. Royalty Pharma captured approximately 40% market share with $4.7 billion in announced transactions.
Diversifying participant base. Beyond the traditional royalty acquirers (Royalty Pharma, HealthCare Royalty, OMERS/DRI), the market now includes Sixth Street (Beam Therapeutics facility), BioPharma Credit, and increasingly private equity firms using royalty structures. Ligand's $1 billion+ in deployable capital positions it as an active mid-market royalty investor focused on funding Phase 3 studies at $30–80 million per program in exchange for royalty economics.
Mainstreaming of non-dilutive capital. Both Ligand CEO Todd Davis and Royalty Pharma CEO Pablo Legorreta emphasized on their respective earnings calls that royalty financing has evolved from a niche tool to a core component of the biotech capital structure toolkit. The convergence of elevated interest rates making traditional debt expensive, biotech equity markets remaining selective, and Big Pharma's patent cliff creating urgency to fund development-stage assets has created structural tailwinds for royalty capital providers.
Growth outlook. Ligand projects a 23% royalty receipts CAGR through 2030. Royalty Pharma targets at least $4.7 billion in annual Portfolio Receipts by 2030 (9%+ CAGR from 2025). These growth rates, if achieved, imply the addressable royalty market will continue expanding materially beyond the current $10 billion level.
Royalty Fund Activity Tracker (Week of Feb 22–27)
A summary of the week's news, earnings, and announcements from the major royalty and non-dilutive capital providers — even where no new transactions were disclosed.
Ligand Pharmaceuticals (Nasdaq: LGND) — Q4/FY2025 Earnings (Feb 26). Ligand reported FY2025 royalty revenue of $161 million (+48% YoY) and total revenue of $268 million. Q4 royalty revenue was $50.5 million (+45% YoY), driven by Filspari ($103M Q4 US net sales, +108% YoY), Ohtuvayre ($178M partial Q4 sales), and Capvaxive. Adjusted EPS of $8.13 exceeded initial guidance by ~30%.
The company reiterated 2026 guidance: $200–225 million royalty revenue (+32% at midpoint), $245–285 million total revenue, and $8.00–9.00 adjusted EPS. Cash and investments of $734 million, plus equity holdings and credit facility, give Ligand over $1 billion in deployable capital.
CEO Todd Davis emphasized accelerating business development in 2026, focused on Phase 3 programs at $30–80 million per deal. VP Lauren Hay disclosed a new systematic portfolio management process for active partner engagement. Key upcoming catalysts: Filspari FSGS PDUFA (April 13, 2026), Qtorin rapamycin NDA submission (H2 2026), Ohtuvayre China NDA under review. (Source)
Royalty Pharma (Nasdaq: RPRX) — TD Cowen Conference Participation (Feb 26); Q4/FY2025 Earnings (Feb 11). No new transactions announced during the reporting week. Royalty Pharma announced February 26 that it will present at TD Cowen's 46th Annual Health Care Conference on March 3.
The company's Q4/FY2025 earnings (February 11) reported Portfolio Receipts of $3.25 billion for FY2025 (+16% YoY), Q4 Portfolio Receipts of $874 million (+18% YoY), and guided 2026 Portfolio Receipts to $3.275–3.425 billion (3–8% Royalty Receipts growth).
CEO Pablo Legorreta noted 2025 was "one of the most remarkable years" in company history, with $2.6 billion deployed on royalty transactions and the royalty funding market reaching a record $10 billion. The company completed internalization of its external manager and repurchased $1.2 billion in shares during 2025. Development-stage pipeline catalysts in 2026 include pivotal results for daraxonrasib (Revolution Medicines), pelacarsen (Ionis/Novartis), and litifilimab (Biogen). (Source)
Separately, MIT announced on February 27 that the MIT-Royalty Pharma Faculty Founder Initiative — a two-year program supporting biotech faculty entrepreneurs in commercializing early-stage research — has been renamed and expanded with a $3 million gift from Royalty Pharma, supporting four years of the initiative through 2029. The program, directed by MIT Professor Sangeeta Bhatia, has supported 21 faculty entrepreneurs across three cohorts, spawned 16 startups that have collectively raised over $70 million in seed funding, and recently expanded internationally with the addition of the University of Oxford as a collaborating institution. The third cohort includes 12 members, six each from MIT and Oxford.
The initiative's stated goal is to reach 40 faculty-founded life science ventures by 2029. While small in transaction scale relative to Royalty Pharma's $2.6 billion annual deployment, the Faculty Founder Initiative is a strategic CSR/brand-building effort that positions Royalty Pharma at the earliest stage of the biotech value chain — upstream of the late-stage royalty transactions that form the company's core business. As Legorreta noted, the initiative supports "bold ideas which can lead to transformative medicines" — precisely the pipeline that may eventually generate royalty-eligible assets. (Source)
HealthCare Royalty (HCRx) — ADCT Royalty Amendment (Feb 23). The only in-window activity was the ADC Therapeutics royalty purchase agreement amendment covered earlier in this report. No other new deals or announcements.
HCRx, now majority-owned by KKR since July 2025, has committed $7+ billion in over 110 biopharmaceutical products since inception and manages approximately $3 billion in assets. CEO Clarke Futch described the ADCT amendment as reflecting "belief in the long-term upside of ZYNLONTA." (Source)
DRI Healthcare Trust (TSX: DHT.UN) — Earnings Call Scheduled (Mar 4); Distribution Declared (Feb 11). DRI announced on February 11 that it will host its Q4/FY2025 earnings call on March 4, 2026. No new transactions during the reporting week.
DRI's most recent deal was its $300 million synthetic royalty acquisition on Viridian Therapeutics' veligrotug and VRDN-003 (announced Q3 2025). The trust declared its quarterly distribution of $0.10 per unit. DRI has deployed more than $3.0 billion since founding in 1989, acquiring 75+ royalties on 50+ drugs. (Source)
Debt and Non-Dilutive Capital
| Date | Issuer | Type | Size | Terms | Source |
|---|---|---|---|---|---|
| Feb 24 | Beam Therapeutics (Nasdaq: BEAM) | Senior secured credit facility | Up to $500M | $100M funded at closing; $300M tied to risto-cel regulatory/commercial milestones; $100M by mutual agreement; ~10% annual interest; no scheduled amortization; secured by substantially all assets; principal due 2033. Beam legal: WilmerHale. Sixth Street legal: Proskauer, Mintz | GlobeNewswire, Globe and Mail |
Beam Therapeutics / Sixth Street $500 Million Credit Facility (Announced February 24)
Beam Therapeutics entered a strategic financing agreement with Sixth Street for up to $500 million in long-term, non-dilutive capital to fund the anticipated launch of risto-cel (base-edited sickle cell disease therapy, BLA submission expected as early as year-end 2026). The facility is structured in tranches: $100 million funded at closing, a further $300 million tied to specified risto-cel regulatory and commercial milestones, and an additional $100 million available by mutual agreement. Principal repayment is due by 2033. The facility is secured by substantially all company assets and includes covenants around minimum liquidity, indebtedness limits, and risto-cel commercialization milestones.
The facility bears approximately 10% annual interest, requires no scheduled amortization, and includes mandatory prepayments from certain asset dispositions. Beam expects a minimum drawdown of $200 million from the facility. Combined with Beam's existing $1.25 billion in cash and marketable securities (as of December 31, 2025), the Sixth Street facility extends expected cash runway into mid-2029 — providing the company with financing durability through the critical risto-cel launch period and continued investment in its in vivo liver-targeted pipeline (BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-301 for glycogen storage disease type Ia, and the newly announced BEAM-304 for phenylketonuria).
Advisors. Beam legal: WilmerHale (led by George Shuster and Nathan Moore). Sixth Street legal: Proskauer Rose LLP (led by partner Frederic Ragucci, Private Credit & Leveraged Finance) and Mintz.
The Sixth Street deal follows a pattern of growth-stage biotechs utilizing structured non-dilutive debt to fund commercial transitions, similar to BioPharma Credit's and Hercules' financings of other cell and gene therapy companies. For Beam specifically, this financing structure avoids the dilution that would accompany an equity raise at current valuation while aligning capital access with the binary milestones that will determine risto-cel's commercial trajectory.
Venture Capital
| Date | Company | Round | Amount | Lead Investor(s) | Therapeutic Focus | Source |
|---|---|---|---|---|---|---|
| Feb 24 | Slate Medicines | Series A | $130M | RA Capital Management, Forbion, Foresite Capital | Migraine; SLTE-1009 (anti-PACAP mAb licensed from DartsBio, China) | Fierce Biotech |
| Feb 24 | Brainomix (UK) | Growth | $25.4M | Parkwalk Advisors, Hostplus (via IP Group), Modi Ventures | AI stroke diagnostics (Brainomix 360 Stroke); e-Lung | Brainomix |
Slate Medicines Series A (Announced February 24)
Slate Medicines, a Raleigh, North Carolina-based biotech, closed a $130 million Series A to advance next-generation migraine therapeutics. The round was led by RA Capital Management, Forbion, and Foresite Capital, with an unnamed biotech investor also participating.
The lead program SLTE-1009 is an anti-PACAP (pituitary adenylate cyclase-activating polypeptide) monoclonal antibody licensed from China's DartsBio Pharmaceuticals. PACAP is a neuropeptide implicated in migraine pathophysiology through a mechanism distinct from calcitonin gene-related peptide (CGRP), the target of all currently approved preventive migraine antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab). First-in-human dosing is targeted for mid-2026. The $130 million Series A is substantial for a single-asset preclinical company, reflecting investor conviction that the anti-PACAP mechanism offers differentiated efficacy in CGRP non-responders — an estimated 40–50% of patients who do not achieve adequate response with current anti-CGRP therapies.
Public Offerings and Equity Financings
| Date | Issuer | Type | Size | Key Details | Source |
|---|---|---|---|---|---|
| Feb 17 (reported Feb 26) | Immunic, Inc. (Nasdaq: IMUX) | Private placement (pre-funded warrants) + synthetic royalty | $200M upfront; up to $400M total | Led by BVF Partners (~9.99% post-deal); includes RA Capital, OrbiMed, Janus Henderson, EcoR1 Capital, others; 5% synthetic royalty on vidofludimus calcium via Royalty Purchase Agreement | PR Newswire, Benzinga |
Immunic $400M Private Placement with Embedded Synthetic Royalty (Closed Feb 17). The placement comprises 229,076,000 pre-funded warrants at $0.873 each plus matching common warrants (expiring 30 days post-ENSURE data or February 17, 2031). The embedded 5% synthetic royalty on vidofludimus calcium global net sales was created by exchanging 51,087,000 May 2025 Series B Warrants into a Royalty Purchase Agreement — royalties payable quarterly after first commercial sale, allocated pro rata among participating warrant holders.
Placement agents: Leerink Partners (lead), Stifel, Guggenheim Securities, William Blair, LifeSci Capital, B. Riley Securities, Brookline Capital Markets. Funds support Phase 3 ENSURE (relapsing MS) top-line data expected year-end 2026, NDA submission mid-2027, and PPMS Phase 3 initiation late 2026. Runway extended to late 2027. | Feb 24 | Brainomix (UK) | Growth equity | $25.4M | AI medical imaging (stroke, lung fibrosis); Parkwalk Advisors, Hostplus (via IP Group), Modi Ventures | Brainomix | | Feb 24 | Octapharma AG | Equity investment | $11.75M | Investment in Abram Scientific (CoagCare™, bleeding disorders diagnostics, preclinical) | Abram Scientific | | Feb 24 | Interactive Venture Partners, Beiersdorf Venture Capital | Equity investment | $25M | Investment in Turbine (immunology, computational biology platform) | Turbine |
IPOs & Listing Filings
The week was headlined by the largest biotech IPO since 2024 — Generate:Biomedicines' $400 million Nasdaq debut — while two Chinese pharmaceutical companies filed for HKEX main board listings, continuing the accelerating pace of Hong Kong biotech listings under the 18A and main board regimes.
| Date | Company | Exchange | Raise / Status | Therapeutic Focus | Bookrunners / Sponsors | Source |
|---|---|---|---|---|---|---|
| Feb 26-27 | Generate:Biomedicines (Nasdaq: GENB) | Nasdaq Global Select | $400M (25M shares @ $16); 30-day option for 3.75M additional shares (~$460M total if exercised) | AI-designed anti-TSLP (severe asthma, Phase 3); COPD; oncology (CAR-T, ADC enhancer) | Goldman Sachs, Morgan Stanley (joint lead); Piper Sandler, Guggenheim Securities, Cantor | PR Newswire |
| Feb 25 | Tianchen Biopharmaceutical (Suzhou) | HKEX Main Board (filed) | Filing; 7 rounds totaling RMB 521.5M (~$72M); post-money valuation >RMB 2B (~$280M) at Series C | Anti-IgE mAb LP-003 (allergic rhinitis Phase 3, CSU Phase 2); dual C5/C3b antibody LP-005 (PNH Phase 2) | Zhongtai International (sponsor) | iFeng Finance |
| Mar 1 | Hanfang Pharmaceutical (Shandong) | HKEX Main Board (filed) | Filing; FY2024 revenue RMB 991M (~$137M), profit RMB 198M (~$27M), 82.5% gross margin | Traditional Chinese medicine (topical dermatology); Class II protected TCM variety | Zhongtai International (sponsor) | iFeng Finance |
Generate:Biomedicines $400 Million Nasdaq IPO (Priced February 26, Trading February 27)
Generate:Biomedicines, a Flagship Pioneering-founded clinical-stage company applying generative AI to protein therapeutics design, priced its initial public offering at $16 per share for 25 million shares, raising $400 million in gross proceeds — the largest biotech IPO since 2024. The company began trading on the Nasdaq Global Select Market on February 27 under the ticker "GENB." Underwriters hold a 30-day option for an additional 3.75 million shares that could bring total proceeds to approximately $460 million.
The platform. Generate's drug discovery engine integrates generative and predictive AI models with high-throughput laboratory capabilities including scalable DNA assembly, rapid protein production, multiplexed assays, and an in-house cryo-EM core. The company has produced over 500 high-resolution cryo-EM maps in 2025 alone. Founded in 2018 by MIT scientists, Generate has raised more than $700 million in venture capital prior to the IPO and has active partnerships with Amgen (up to $1.9 billion, 6 programs) and Novartis (over $1 billion potential value).
The pipeline. Generate's lead asset GB-0895 is an AI-designed anti-TSLP monoclonal antibody engineered for every-26-weeks dosing in severe asthma — a significant dosing advantage over existing biologics including AstraZeneca/Amgen's Tezspire (every 4 weeks). Two global Phase 3 trials (SOLAIRIA-1 and SOLAIRIA-2) are underway, with the first patient dosed January 26, 2026 and enrollment of approximately 1,600 patients expected. An additional Phase 1b study in COPD is planned. Beyond respiratory, Generate's oncology pipeline includes GB-4362 (a monoclonal antibody designed to neutralize free MMAE to improve tolerability of MMAE-based ADCs, planned Phase 1 in metastatic urothelial cancer) and GB-5267 (an armored MUC16-directed CAR-T for platinum-resistant ovarian cancer, Phase 1 planned 2026).
Strategic context. Generate's IPO is significant for several reasons. First, it validates the AI drug discovery thesis at scale — the $400 million raise is the largest IPO by an AI-native biotech to date, exceeding Eikon Therapeutics' $381 million listing earlier in February. Second, the anti-TSLP asthma market addresses approximately 1.9 million eligible patients in the US, EU5, and Japan, with global asthma biologics projected to reach $13 billion by 2034.
Third, the company had $221.5 million in cash at year-end 2025 and a $676.3 million accumulated deficit, making the IPO proceeds essential for Phase 3 completion. CEO Mike Nally, former Chief Marketing Officer at Merck, told Fierce Biotech the team had "worked feverishly over the Thanksgiving holiday" to ready the IPO for February, reflecting urgency to capitalise on the reopening biotech IPO window.
Use of proceeds. Approximately $300 million for two Phase 3 severe asthma trials; $100 million for Phase 1b COPD study; $75 million for platform innovation and IND-enabling activities; $15 million for GB-4362 and GB-5267 clinical programs.
Advisors. Goldman Sachs & Co. LLC and Morgan Stanley (joint lead book-running managers); Piper Sandler, Guggenheim Securities, and Cantor (book-running managers).
Tianchen Biopharmaceutical HKEX Filing (February 25)
Tianchen Biopharmaceutical (Suzhou), a clinical-stage innovative biotech founded in October 2020, submitted its listing application to the HKEX main board with Zhongtai International as sole sponsor. The company has completed seven financing rounds totaling RMB 521.5 million (~$72 million), with a post-investment valuation exceeding RMB 2 billion (~$280 million) at its May 2025 Series C. Investors include Eastern Fortune Capital (>7% stake, largest institutional holder), Qiming Venture Partners (4.27%), Honghui Fund (3.98%), Shizhenyitang (CSPC/Shizhenyitang Group background), and Betta Pharma. Co-founders Liu Heng (43, CEO) and Sun Naichao (89, executive director) hold 44.16% as concert parties.
The science. Tianchen Bio's story is notable because co-founder Dr. Sun Naichao was one of the principal inventors of omalizumab (Xolair) — the $4.4 billion anti-IgE blockbuster jointly owned by Novartis and Roche — during his tenure at Tanox (NASDAQ-listed, later acquired by Genentech).
His core product LP-003 is a next-generation anti-IgE monoclonal antibody designed to surpass the drug he himself invented 30 years ago. Preclinical data show LP-003 binds IgE with 860-fold higher affinity (Kd 2.08 pM vs. 1,790 pM for omalizumab) and demonstrates 30x greater potency in blocking IgE-FcεRIα binding. In a head-to-head Phase 2 study in chronic spontaneous urticaria (151 patients), LP-003 (200mg Q4W) achieved complete symptom control (UAS7=0) in 44.8% of patients at Week 4 versus 13.3% for omalizumab at the same frequency, and 60.0% versus 41.4% at Week 12. Critically, LP-003's half-life of 45–76 days (vs. ~20 days for omalizumab) enables potential every-12-week dosing — a major adherence advantage for chronic allergy management.
LP-003's lead indication (moderate-to-severe seasonal allergic rhinitis) has completed Phase 3 enrollment (546 patients) with completion expected H1 2026 and NDA submission to China's NMPA planned for Q3 2026 or earlier. Additional Phase 2 trials in allergic asthma and CRSwNP are using a Q12W (every 12 weeks) dosing regimen.
Second pipeline asset LP-005. Tianchen's dual-function C5/C3b complement inhibitor LP-005 addresses the limitation of single-target complement drugs (e.g., eculizumab) by simultaneously blocking classic, alternative, and lectin complement pathways. Phase 2 interim data in PNH (20 patients, 12 weeks) showed LDH reduction of 82.5% in the high-dose cohort and 100% transfusion avoidance, including two patients who had failed prior eculizumab therapy. The dual-target approach directly addresses the compensatory C3 activation that causes breakthrough hemolysis in C5-only inhibitors.
Financials. Tianchen Bio reported zero revenue, with total comprehensive losses of RMB 95.8 million (2023), RMB 137 million (2024), and RMB 138 million (9M 2025). R&D expenses consumed 79–92% of operating costs. The company follows a strict asset-light CDMO model — it dissolved its manufacturing subsidiary in May 2025 after concluding outsourced production was more capital-efficient than self-built capacity. Cash and equivalents were approximately RMB 191 million ($26 million) as of December 31, 2025. The company is targeting a significant Chinese allergy biologics market projected to grow from RMB 2 billion (2024) to RMB 12.1 billion (2030), a 32.5% CAGR.
Hanfang Pharmaceutical HKEX Filing (March 1)
Shandong-based Hanfang Pharmaceutical, a traditional Chinese medicine company, filed its HKEX main board listing application with Zhongtai International as sole sponsor. Unlike the pre-revenue biotechs typical of HKEX 18A filings, Hanfang is a profitable, commercial-stage TCM company.
The company generated revenue of RMB 1.052 billion (2023), RMB 991 million (2024), and RMB 802 million (9M 2025), with consistent gross margins above 82% and net profits of RMB 237 million (2023), RMB 198 million (2024), and RMB 144 million (9M 2025). Over 99% of revenue derives from a single product — "Compound Phellodendron Amurense Liquid Topical Solution" — a Class II protected traditional Chinese medicine variety with legally exclusive market positioning under China's TCM variety protection regulations.
The company ranked fourth in China's topical TCM preparations market by sales revenue in 2024 (1.1% market share, per Frost & Sullivan). Distribution accounts for over 90% of sales through approximately 930 distributors (as of 9M 2025).
The company is 100% family-controlled: Chairman Qin Wenji holds 90% and his brother, General Manager Qin Yinji, holds 10%. Hanfang is attempting to diversify beyond its single-product dependency through cosmetics (skincare brand "Slaor" leveraging phellodendron bark extract) and classic TCM formulas (Angong Niuhuang Wan, Wuji Baifeng Wan), though these remain early-stage with minimal revenue contribution.
Radiopharmaceutical Deals
Two radiopharmaceutical transactions this week reflect the sector's continued momentum following the wave of large-cap acquisitions (AstraZeneca/Fusion, Bristol Myers/RayzeBio, Eli Lilly/Point) that have reshaped the space.
NantWorks / SHINE Technologies — $240M Lu-177 Supply & Equity Investment (Feb 26). SHINE Technologies completed a $240 million equity fundraise led by NantWorks founder Dr. Patrick Soon-Shiong ($150M), with additional participation from Fidelity Management & Research Company, Sumitomo Corporation of Americas, Pelican Energy Partners, Deerfield Management, Oaktree Capital Management, and other existing investors. SHINE has now raised more than $1 billion in total funding to date.
The deal includes priority access arrangements for SHINE's non-carrier-added lutetium-177 (Ilumira brand) supply for NantWorks' radiopharmaceutical programs, positioning both organizations to explore combining targeted Lu-177 radiation with immune activation approaches. SHINE operates the Cassiopeia facility in Janesville, Wisconsin — one of the largest non-carrier-added Lu-177 production facilities in North America, with capacity for up to 100,000 doses annually and the ability to scale to 200,000 doses per year.
Ilumira has shipped to customers in 19 countries across four continents, achieving greater than 95% on-time, in-full delivery since its commercial launch in 2024. SHINE submitted a Drug Master File to the FDA for n.c.a. Lu-177 in 2024 and is commissioning the larger Chrysalis facility for commercial-scale isotope production. Soon-Shiong joins SHINE's board. The investment highlights growing concern over Lu-177 supply constraints as the market scales from Novartis' Pluvicto to a growing pipeline of Lu-177-based therapies. PR Newswire
Radiopharm Theranostics (ASX: RAD; Nasdaq: RADX) / AtomVie Global Radiopharma — 177Lu-BetaBart First Patient Dosed (Feb 24). AtomVie supplied the first patient dose in Radiopharm's FIH Phase 1/2a trial of 177Lu-BetaBart (RV-01), a lutetium-177-conjugated monoclonal antibody targeting the 4Ig isoform of B7-H3 — an immune checkpoint molecule overexpressed across multiple solid tumour types with minimal expression in normal tissue. RV-01 was developed through Radiopharm Ventures, a JV with MD Anderson Cancer Center.
The dose-escalation study (NCT07189871) plans to enrol 61 patients across prostate, colorectal, NSCLC, SCLC, TNBC, ovarian, cervical, endometrial, head & neck, and oesophageal cancers. AtomVie, the Canadian radiopharmaceutical CDMO, is commissioning a new 72,300 sq ft facility for operational readiness in H2 2026. PR Newswire
Oncoinvent ASA (OSE: ONCIN) — Radspherin® Phase 1 Data at ESGO & H2 2025 Results (Feb 26). Oncoinvent (which completed its merger with BerGenBio in Oct 2025 and raised NOK 130M in a rights issue) presented positive final 24-month Phase 1 follow-up data for Radspherin® at ESGO 2026 in Copenhagen. Radspherin is a receptor-independent alpha-emitting radiopharmaceutical (radium-224 microparticles) administered intraperitoneally to eliminate micro-metastases after surgical resection. Results were striking: of 10 patients treated at the recommended 7 MBq dose, only 1 experienced peritoneal recurrence at 24 months. No grade ≥3 AEs were related to treatment.
A randomised Phase 2 trial (NCT06504147) comparing PFS in ovarian cancer patients is actively recruiting across 10 sites in Norway, Spain, Belgium, UK, US, and Italy, with FDA Fast Track designation. The company's CEO, Øystein Soug, previously co-led the sale of alpha-radiopharmaceutical company Algeta (Xofigo/radium-223) to Bayer. PR Newswire, Oncoinvent
New Clinical Assets & Licensing Deals
IDEAYA Biosciences (Nasdaq: IDYA) / Biocytogen (HKEX: 02315) — IDE034 First Patient Dosed, $5M Milestone (Feb 25). IDEAYA dosed the first patient in its Phase 1 trial of IDE034, a potential first-in-class B7H3/PTK7 bispecific TOP1 ADC, triggering a $5 million milestone payment to Biocytogen under their July 2024 Option and License Agreement (total deal value up to $400M in milestones + royalties). IDE034 is designed to internalise only when both target antigens are co-expressed on the same tumour cell, which may enhance selectivity relative to monovalent B7H3 ADCs. IDEAYA estimates B7H3/PTK7 co-expression in approximately 30-40% of lung, breast, ovarian, and colorectal cancers, with minimal dual expression in normal tissue.
The company plans to explore combinations with its proprietary PARG inhibitor IDE161. IDEAYA had ~$1.05B in cash as of year-end 2025. PR Newswire
Antengene (SEHK: 6996) / Shanghai Junshi Biosciences (HKEX: 1877; SSE: 688180) — ATG-037 + JS207 Clinical Collaboration (Feb 24-25). The two Chinese biotechs will jointly evaluate a "triple-axis" immuno-oncology combination in solid tumours: Antengene's ATG-037 (oral small-molecule CD73 inhibitor) combined with Junshi's JS207 (anti-PD-1/VEGF bispecific antibody). The rationale targets immune checkpoint signalling, angiogenesis, and the adenosine pathway simultaneously. JS207 already has 11 ongoing Phase 2 studies with ~500 patients enrolled and has demonstrated a 58.1% ORR in PD-L1-positive NSCLC (1L monotherapy, ESMO Asia 2025). The FDA has approved an IND for a Phase 2/3 study of JS207 vs. nivolumab in neoadjuvant NSCLC. Clinical collaboration in Mainland China; terms undisclosed. PR Newswire (Antengene), GlobeNewswire (Junshi)
GEMMABio / Oswaldo Cruz Foundation (Fiocruz) — GB221 First Patient Dosed in CHARISMA Trial (Feb 26). GEMMABio dosed the first patient in its Phase 1/2 CHARISMA trial of GB221, a next-generation gene therapy for SMA Type 1. The programme is backed by an Oct 2024 partnership worth up to $100M. GB221 aims to improve on current SMA gene therapies (Zolgensma) with potentially broader patient eligibility. PR Newswire
Anixa Biosciences (Nasdaq: ANIX) / Cleveland Clinic — Cancer Vaccine Licensing (Feb 23). Anixa highlighted its Cleveland Clinic-licensed breast and ovarian cancer vaccine portfolio (Cleveland Clinic entitled to royalties and commercialisation revenues) alongside clinical progress of its CAR-T programme at the SCTR 2026 Retreat. Anixa's liraltagene autoleucel (lira-cel) — an FSHR-targeted CER-T (chimeric endocrine receptor-T) therapy for recurrent ovarian cancer — is in a Phase 1 trial at Moffitt Cancer Center (NCT05316129). Encouraging survival data: 7 of 12 treated patients have lived beyond their expected 3-4 month median survival. No DLTs observed across four dose levels, and a protocol amendment now permits escalation from 10⁷ to 10⁹ cells/kg. PR Newswire
Genprex (Nasdaq: GNPX) — Reqorsa® Gene Therapy IP Expansion (Feb 23). Genprex secured patent grants from the Japanese Patent Office and European Patent Office for Reqorsa (quaratusugene ozeplasmid) in combination with PD-1/PD-L1 antibodies for cancer treatment. Reqorsa is a non-viral lipid nanoparticle gene therapy delivering the TUSC2 tumour suppressor gene, currently in two Phase 1/2 clinical trials: Acclaim-1 (NSCLC) and Acclaim-3 (ES-SCLC, in combination with Genentech's Tecentriq). Both programmes have FDA Fast Track designation; the SCLC programme also has Orphan Drug designation. Phase 2 interim analysis expected H2 2026. Genprex holds an exclusive license from UT MD Anderson and recently added a University of Michigan license for ALK-inhibitor combinations. PR Newswire
Supply Agreements & CDMO
Bora Pharmaceuticals / GSK — $250M Five-Year Global Manufacturing Contract (Feb 23). Bora Pharmaceuticals (TWSE: 6472; OTCQX: BORAY) and GSK signed a strategic agreement to renew and expand a five-year global manufacturing partnership valued at approximately $250 million, extending through 2030. GSK is the largest pharmaceutical partner at Bora's 170,000-square-foot Mississauga, Ontario facility — originally acquired from GSK in 2020 — where Bora provides end-to-end manufacturing services for more than 20 commercial GSK product lines and over 335 individual products across therapeutic areas including HIV, malaria, pneumonia, parasitic infections, depression, migraine, acne, eczema, and psoriasis.
The renewed agreement expands beyond the Mississauga site, granting GSK access to multiple facilities within Bora's growing North American network, including its newest oral solid dose (OSD) plant in Maple Grove, Minnesota (acquired through the $210 million Upsher-Smith buyout in 2024) and its sterile manufacturing facility in Baltimore (acquired from Emergent BioSolutions in 2024). Since joining the Bora network, the Mississauga facility has expanded to support 32 total clients, advanced 61 products, and completed more than 400 project and development batches.
The deal illustrates several broader trends in pharmaceutical manufacturing: the transition from single-site CDMO engagements to multi-site, multi-capability platform partnerships; the lengthening of contract terms from transactional to strategic (five-year commitments with implicit renewal expectations); and the maturation of the pharma-to-CDMO asset transfer model, where facilities divested by Big Pharma are now being leveraged by CDMOs to serve the original seller alongside a diversified client base.
For GSK specifically, the deal ensures continuity of supply for a large legacy product portfolio while the company's M&A and licensing activity (35Pharma, Frontier siRNA, Aicuris via Veloxis, bepirovirsen regulatory filings) increasingly focuses capital on innovative pipeline assets.
Gene Therapy Distribution, Ultra-Rare Disease Supply & Veterinary Cell Therapy
Orsini / Genetix Biotherapeutics — Gene Therapy Specialty Pharmacy Partnership (Feb 26). Orsini, a specialty pharmacy focused on rare disease, was selected by Genetix Biotherapeutics (formerly bluebird bio, taken private by Carlyle and SK Capital in June 2025) as a specialty pharmacy partner for three FDA-approved gene therapies: LYFGENIA (sickle cell disease), ZYNTEGLO (β-thalassemia), and SKYSONA (cerebral adrenoleukodystrophy). These are among the most expensive therapies on the market ($2.8M–$3.1M per treatment), and logistics are complex given the autologous cell therapy manufacturing process. Orsini's Cell and Gene Therapy Center of Excellence now supports a total of 12 therapies. PR Newswire
Ipsen / Quotient Sciences — Sohonos (palovarotene) Supply Extension (Feb 26). Quotient Sciences extended its commercial manufacturing partnership with Ipsen for Sohonos, which treats fibrodysplasia ossificans progressiva (FOP) — an ultra-rare condition affecting approximately 900 patients globally. FOP causes soft tissue to progressively turn to bone. PR Newswire
MWI Animal Health (Cencora) / Gallant — Sonruvetcel Veterinary Cold-Chain Partnership (Feb 27). MWI Animal Health, part of Cencora, signed a fulfillment agreement with Gallant to build the first ultra-low temperature cold chain for veterinary medicine. The partnership will support nationwide distribution of Gallant's lead candidate, sonruvetcel — a potential first-in-class uterine-derived allogeneic mesenchymal stromal cell (MSC) therapy for cats with refractory feline chronic gingivostomatitis (rFCGS). MWI will ship from its Edwardsville, Kansas distribution center via overnight shipping to clinics across the continental US, Alaska, Hawaii, and Puerto Rico. Sonruvetcel is sourced from healthy, specific-pathogen-free, FDA-qualified feline donors and manufactured under cGMP conditions.
The therapy has achieved FDA-CVM "Technical Section Complete" for both Target Animal Safety (365-day data, Nov 2025) and Reasonable Expectation of Effectiveness (Sep 2025), with conditional approval targeted for early 2026 — which would make it the first FDA-approved, ready-to-use stem cell therapy in veterinary medicine.
In a pivotal trial published in the Journal of Feline Medicine and Surgery, over 75% of treated cats showed clinically relevant improvement in quality of life by Day 90. An AAHA survey conducted by Gallant found that nearly 95% of veterinary professionals believe stem cell therapy will become a standard treatment option within the next decade, and 93% reported they would be more likely to offer regenerative therapies if they were off-the-shelf and delivered through a simple IV protocol. Gallant raised $18M in Series B funding (Jul 2025) and its pipeline extends to feline and canine osteoarthritis, canine atopic dermatitis, and feline chronic kidney disease. The deal is notable as a veterinary parallel to the human cell therapy logistics challenges seen in gene therapy distribution. PR Newswire
GLP-1 Market: Generic Saxenda Launch
Cipla USA / Orbicular Pharmaceuticals — Generic Saxenda (Liraglutide) US Launch (Feb 27). Cipla USA, the wholly owned subsidiary of Cipla Limited (BSE: 500087; NSE: CIPLA), launched generic liraglutide injection (18 mg/3 mL prefilled pens) — the generic equivalent of Novo Nordisk's Saxenda — for chronic weight management in the US. The ANDA was obtained by Cipla's partner Orbicular Pharmaceutical Technologies (India), which is the ANDA holder. Cipla leads marketing and distribution with immediate commercial availability. Liraglutide is a synthetic GLP-1 analogue sharing 97% amino acid similarity with the natural hormone, originally approved in the EU in 2009 and the US in 2010 (as Victoza for T2D), with the weight management indication (Saxenda) approved in 2014. Cipla is now one of the few companies offering generic versions of both Victoza and Saxenda in the US, alongside Teva and Meitheal Pharmaceuticals (which launched generic liraglutide in 2025).
According to IQVIA (MAT December 2025), the total addressable market for GLP-1 therapies in weight management in the US was approximately $127 million — a figure that primarily reflects the branded Saxenda price point in a market now rapidly migrating to next-generation weekly injectables (semaglutide/Wegovy, tirzepatide/Zepbound). The launch is contextually relevant alongside this week's Novo Nordisk/Vivtex $2.1 billion oral biologics collaboration, which aims to develop oral formulations of large-molecule GLP-1/GIP agonists that could displace the current injectable delivery paradigm entirely. PR Newswire
Grants, Research Collaborations & Other
| Date | Party A | Party B | Asset / Focus | Deal Type | Terms | Source |
|---|---|---|---|---|---|---|
| Feb 24 | ARPA-H | Sam and Ann Barshop Institute | Rapamycin, dapagliflozin, semaglutide (aging, 60–65 year-olds) | Government grant | $38M | ARPA-H |
| Feb 24 | AstraZeneca | Lung Cancer Research Foundation | Oncology research collaboration | Grant/Collab | $750K | LCRF |
| Feb 24 | Hoth Therapeutics | Regis Clinical Research | HT-001 (EGFR inhibitor skin toxicities) | Clinical collaboration | Undisclosed | Hoth Therapeutics |
| Feb 24 | Azitra Inc. | UT MD Anderson Cancer Center | ATR-04 (EGFRi skin rash) | Clinical collaboration | Undisclosed | Azitra |
| Feb 26 | Havas Health | BrightInsight | Digital health patient adherence platform (exclusive global agency partnership) | Collaboration | Undisclosed | PR Newswire |
| Feb 25 | GE HealthCare | Gentuity LLC | Cardiology imaging (intravascular OCT) | Collaboration | Undisclosed | Gentuity |
| Feb 26 | Breakthrough T1D (fmr. JDRF) | SanMar Corporation | Type 1 diabetes awareness (National Walk Series sponsorship) | Collaboration | $2.7M (2025 Seattle walk) | PR Newswire |
| Feb 26 | Healthcare Triangle, Inc. (Nasdaq: HCTI) | D. Boral Capital (placement agent) | Healthcare IT (registered direct offering, 681,553 shares at $5.81) | Equity offering | $3.96M | PR Newswire |
SEC Filings and Regulatory Developments
Several SEC filings during the week provided additional transaction detail and corporate updates relevant to the deal landscape:
BioMarin Pharmaceutical (Feb 23): FY2025 earnings release confirmed Amicus acquisition expected to close Q2 2026 following March 3 stockholder vote. The company secured $3.7 billion in non-convertible debt financing with strong demand. BioMarin also disclosed it is seeking to divest ROCTAVIAN (hemophilia A gene therapy) and has withdrawn the product from the market — a notable failure event for a $2.9 million per-dose gene therapy that speaks to the challenges of gene therapy commercial adoption.
Vanda Pharmaceuticals / AnaptysBio imsidolimab (Feb 25): FDA accepted Vanda's BLA filing for imsidolimab (anti-IL-36R mAb) for generalized pustular psoriasis (GPP), with a PDUFA target action date of December 12, 2026. The asset was licensed from AnaptysBio in February 2025 for $10 million upfront plus $5 million for drug supply, with AnaptysBio eligible for up to $35 million in regulatory and sales milestones and a 10% royalty on global net sales.
Advisors on the 2025 license: AnaptysBio — Guggenheim Securities (financial), Fenwick & West (legal). Vanda — Cantor Fitzgerald (financial), Orrick Herrington & Sutcliffe (legal). In GEMINI-1 and GEMINI-2 Phase 3 trials, 53% of patients achieved GPPPGA 0/1 (clear or almost clear skin) at Week 4 following a single IV dose versus 13% on placebo, with efficacy maintained during approximately 2 years of monthly maintenance dosing and no flares in the active arm.
If approved, imsidolimab would compete with Boehringer Ingelheim's Spevigo (spesolimab), the first approved IL-36 pathway therapy for GPP flares (approved September 2022). GPP prevalence is estimated at 2–124 cases per million worldwide. This would be Vanda's third new product approval in 12 months, following Nereus (tradipitant) and Bysanti (milsaperidone). For AnaptysBio, the 10% royalty on a rare disease orphan drug with exclusivity extending into the late 2030s could become a meaningful long-term revenue stream.
Beam Therapeutics (Feb 24): Q4/FY2025 10-K and earnings disclosed the Pfizer option exercise and Sixth Street credit facility. Cash and marketable securities of $1.25 billion at year-end 2025 (up from $850.7 million a year earlier). R&D expenses of $409.6 million for FY2025. The company announced BEAM-304 for phenylketonuria (PKU), with IND filing planned in 2026 — expanding the liver-targeted genetic disease franchise beyond BEAM-302 (AATD) and BEAM-301 (GSD-Ia).
Gilead Sciences (Feb 23): 8-K and merger agreement filed in connection with the Arcellx acquisition. The filing disclosed the tender offer structure, CVR terms, and break-fee provisions.
ADC Therapeutics (Feb 23): 8-K disclosing the amended royalty purchase agreement with HealthCare Royalty, including warrant issuance details (9,834,776 shares, $3.8130 exercise price, cashless exercise mechanics, deemed exercise provisions in major corporate transactions).
Ligand Pharmaceuticals (Feb 26): Q4/FY2025 earnings release and 8-K reporting FY2025 royalty revenue of $161.0 million (+48% YoY), total revenue of $268.1 million, GAAP net income of $124.5 million, and core adjusted EPS of $8.13 (+42% YoY). Reiterated 2026 guidance of $245–285 million revenue and $8.00–$9.00 adjusted EPS. Cash and investments of $733.5 million at year-end. Key portfolio highlights: Palvella's Qtorin rapamycin hit positive Phase 3 results in microcystic lymphatic malformations (Feb 24); Travere's Filspari reached $103 million in Q4 US net sales (+108% YoY); LeonaBio acquired lasofoxifene development rights alongside a $90 million PIPE. Management noted $1 billion+ in deployable capital and projected 23% royalty receipts CAGR through 2030.
Royalty Pharma (Feb 11 earnings; Feb 26 conference announcement): Q4/FY2025 results reporting Portfolio Receipts of $3,254 million (+16% YoY), Royalty Receipts of $3,127 million (+13% YoY), and net cash from operations of $827 million in Q4. Deployed $2.6 billion on royalty transactions in 2025; announced $4.7 billion in total transactions (~40% market share). Repurchased 37 million shares for $1.2 billion. 2026 Portfolio Receipts guidance: $3,275–3,425 million. On February 26, announced fireside chat at TD Cowen's 46th Annual Health Care Conference on March 3. Key 2026 catalysts include pivotal readouts for daraxonrasib, pelacarsen, and litifilimab, plus PDUFA for zidesamtinib (September 18, 2026).
Regional Regulatory Milestones (Japan & China)
GSK had an exceptionally active regulatory week across Asia, with two significant filings accepted on the same day — one in Japan and one in China — alongside its $950 million 35Pharma acquisition and $1.0 billion Frontier siRNA licensing deal. These milestones extend GSK's hepatology pipeline into two of Asia's largest markets.
GSK — Bepirovirsen NDA Accepted for Review by Japan MHLW (Feb 26). Japan's Ministry of Health, Labour and Welfare accepted for review a new drug application for bepirovirsen, an investigational antisense oligonucleotide for adults with chronic hepatitis B (CHB). This represents the first regulatory filing globally for bepirovirsen, a potential first-in-class therapy licensed from Ionis Pharmaceuticals. The submission is supported by positive Phase III B-Well 1 and B-Well 2 trial data (conducted across 29 countries), in which bepirovirsen plus standard of care demonstrated statistically significant and clinically meaningful functional cure rates versus standard of care alone. Nearly 1 million people in Japan live with CHB, a leading cause of liver cancer.
Bepirovirsen was granted SENKU designation (Japan's expedited review pathway, formerly SAKIGAKE) in August 2024, and also holds FDA Fast Track designation and China Breakthrough Therapy designation. Bepirovirsen is a triple-action ASO designed to inhibit viral genome replication, suppress hepatitis B surface antigen (HBsAg) in blood, and stimulate immune system response. Functional cure — sustained undetectable HBV DNA and HBsAg for at least 24 weeks after stopping all treatment — is associated with significant reduction in long-term liver complications, including liver cancer. Current standard of care (nucleos(t)ide analogues) often requires lifelong therapy and achieves functional cure rates of only approximately 1%.
GSK — Linerixibat NDA Accepted for Priority Review by China NMPA (Feb 26). China's National Medical Products Administration accepted for priority review GSK's new drug application for linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC), a rare autoimmune liver disease. Linerixibat is an investigational oral inhibitor of the ileal bile acid transporter (IBAT), designed to reduce mediators of cholestatic pruritus — an internal and relentless itch that can be debilitating, leading to chronic sleep disruption and psychological distress. The submission is based on positive data from the Phase III GLISTEN trial (presented at EASL 2025), which met both primary and key secondary endpoints, demonstrating rapid, significant, and sustained improvement in cholestatic pruritus and itch-related sleep interference versus placebo.
In China, approximately 280,000 people are affected by PBC, and up to 89% may experience cholestatic pruritus during the course of their illness — with few effective treatment options available. Linerixibat holds Orphan Drug Designation in the US, EU, and Japan, and marketing applications are currently under review in the US, EU, UK, and Canada. Linerixibat is not yet approved anywhere in the world.
AI in Drug Development
Shionogi / Hitachi — Generative AI Regulatory Document Authoring Solution (Feb 24). Hitachi entered a licensing agreement with Shionogi to commercialise a generative AI solution that supports the creation of regulatory documents in drug development. The solution has been available to pharmaceutical and healthcare companies in Japan since February 2026, with plans to position it under Hitachi's Lumada portfolio. The tool addresses one of the most time-consuming tasks in drug development: creating clinical trial protocols and reports that meet international standards including ICH-E6 and ICH-E3. In a proof of concept conducted at Shionogi, the system reduced preparation time for clinical trial reports by approximately 50% and for clinical trial protocols by roughly 20%.
The solution combines Hitachi's generative AI and pharmaceutical IT capabilities with Shionogi's medical writing expertise and data science capabilities, and can extract and summarise relevant information from large volumes of mixed Japanese and English clinical data, generating initial drafts through an intuitive interface. Hitachi plans to expand this approach into the biopharmaceutical space as part of its broader industry automation strategy. While small in commercial scope, the deal is notable as one of the first Japan-originated AI-in-regulatory-affairs licensing agreements between a major pharma company and a technology conglomerate — a category that is likely to see significant deal activity as AI tools mature for GxP-regulated environments.
Market Context
The week's deal activity demonstrates six persistent themes in 2026 biopharma dealmaking:
Cell therapy consolidation continues. Gilead's $7.8 billion Arcellx acquisition follows Eli Lilly's $2.4 billion Orna Therapeutics deal (February 9) and underscores Big Pharma's conviction that cell therapy — whether autologous CAR-T, in vivo CAR, or gene editing — represents a durable commercial franchise opportunity. Gilead's willingness to pay a 79% premium for a pre-approval asset reflects both the validated competitive landscape (Carvykti's $1.9 billion in 2025 sales) and the strategic imperative to own manufacturing infrastructure and IP in an increasingly crowded market.
Activin signaling and pulmonary hypertension emerge as a new battleground. GSK's $950 million bet on 35Pharma's HS235 follows Merck's Winrevair approval and signals that large pharma views the PH market as capable of supporting multiple differentiated entrants. The key question is whether next-generation activin inhibitors with improved BMP selectivity can capture meaningful share from Winrevair or whether first-mover advantage will prove decisive.
Oral biologics remain the holy grail for metabolic disease. Novo Nordisk's $2.1 billion Vivtex collaboration, combined with the recent Eli Lilly orforglipron data and multiple competitors pursuing oral GLP-1 and multi-agonist formulations, confirms that the obesity/diabetes market's long-term trajectory will be determined by which companies crack the oral biologics delivery challenge. The shift from injectable-first to oral-first will fundamentally change patient economics, payer dynamics, and competitive positioning across the $100+ billion metabolic disease market.
T-cell engagers gain Big Pharma validation in solid tumors. Astellas' $1.7 billion VIR-5500 deal adds to a growing wave of TCE collaborations — including BMS/Harbour BioMed (December 2025), Janux/multiple partners, and Amgen's xaluritamig program — that collectively signal pharma's conviction that masking and engineering innovations can solve the therapeutic index limitations that constrained first-generation bispecifics. The Astellas deal is particularly notable for structuring a 60/40 cost share with co-promote rights — a framework that preserves biotech upside while accessing pharma commercial infrastructure in a category (prostate cancer) where Astellas has established dominance through Xtandi.
China-to-West asset flow accelerates across deal structures. Three of the week's major licensing deals originated from Chinese biotechs: GSK/Frontier (siRNA, $1.0B), Harbour/Solstice (CTLA-4, $1.2B), and the DartsBio asset underlying Slate Medicines' Series A. In the reverse direction, Pfizer China's $495 million commercialisation deal with Sciwind Biosciences for ecnoglutide (an approved biased GLP-1 RA) demonstrates that the China deal flow is increasingly bidirectional — Western pharma is not only licensing assets out of China but also licensing into China to access the domestic obesity/metabolic market.
The Harbour/Solstice "NewCo" model — where the Chinese originator takes equity in a newly formed Western entity — is becoming a preferred structure that preserves upside participation while enabling global development with specialized investors. As one analyst noted this week, China is no longer a "bargain basement" for biotech licensing; average upfront values for China-originated deals have risen substantially, reflecting both the quality of assets emerging from China's biotech ecosystem and the competitive dynamics of multiple Western bidders for the best programs.
Report compiled March 1st, 2026 or p05.org weekly deal report. Transaction values represent announced figures; actual values may vary upon closing. Deals with undisclosed terms are noted but not included in aggregate value calculations. This report is for informational purposes only. The author is not a lawyer or financial adviser and this content does not constitute investment or legal advice.
Member discussion